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ABSTRACT
Here, we present data supporting low density lipoprotein receptor-related protein-1 (LRP1) and urokinase plasminogen activator (uPA) involvment in the suprachiasmatic nucleus
(SCN), the primary mammalian circadian pacemaker. Previous work using extracellular
recordings of SCN neurons in ex vivo hypothalamic slices demonstrated that tissue-type
plasminogen activator (tPA) gates glutamate-induced phase shifts via plasmin-dependent
maturation of brain derived neurotrophic factor (BDNF) and subsequent tropomysin
receptor kinase B (TrkB) receptor activation. Here, we find first, that tPA knockout mice
(tPA−/−; B6.129S2-Plattm1Mlg/J) exhibit minimal phase shifting deficits in vivo and in vitro,
and that uPA compensates for the lack of tPA to enable phase shifts in these mice.
Intriguingly, the data support tPA, but not uPA, acting via BDNF maturation, suggesting
functional compensation achieved through differential mechanisms. Second, we find that
LRP-1 also regulates SCN phase shifting. Inhibiting LRP-1 with receptor associated
protein (RAP) or anti-LRP-1 antibody prevents glutamate-induced phase delays and
advances in neuronal activity rhythms in vitro at ZT16 and ZT23, respectively. We then
turned our attention to potential interactions between tPA and LRP-1, and through three
lines of evidence demonstrate that tPA proteolytic activity is not necessary for LRP-1’s
permissive effect on phase shifting: 1) RAP inhibits phase shifts in tPA-/- SCN, 2) inhibiting
LRP-1 does not impact BDNF maturation, or 3) Trk receptor phosphorylation on Y680/681.
Suprisingly, inhibiting LRP-1 with RAP changes N-Methyl_D-aspartic acid receptor
(NMDAR) phosphorylation patterns in the SCN in vitro, by decreasing phosphorylation on
S1480 of NR2B subunits. Finally, we evaluated uPA and tPA expression and proteolytic
activity across the circadian day, and LRP-1 expression and phosphorylation patterns.
We find evidence of circadian rhythms in tPA expression but not proteolytic activity, no
rhythms in uPA expression or proteolytic activity, and potential diurnal variations in αLRP1 but not βLRP-1 subunits. Additionally, uPA activity and βLRP-1 expression exhibit
changes that correlate with the time slices are maintained in vitro, suggesting that a
response to slicing injury may occlude an accurate view of expression patterns in the SCN
in vitro. Collectively, the data presented here implicate uPA and LRP-1 in the processes
gating glutamate-induced phase shifts in the SCN.
iii
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1 INTRODUCTION
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1.1 Circadian Rhythms
1.1.1

Circadian timekeeping mechanisms and the SCN
To cope with life on this planet with its 24 hour (h) rotation, organisms have

developed internal timekeeping mechanisms that allow them to predict and adapt to daily
changes in the environment. These internal oscillatory systems generate approximately
24 h (circadian) cycles in behavior, physiology, and metabolism, enabling organisms to
coordinate their activities with the environment. Nearly all organisms, ranging from single
celled cyanobacteria to humans, exhibit circadian rhythms. These rhythms are present in
a plethora of physiological processes, including metabolism, hormone secretion, and
sleep-wake cycles. The ability to anticipate and respond to environmental changes,
notably the light-dark cycle, is thought to confer evolutionary advantages, and disruptions
of internal timekeeping mechanisms or asynchrony between the internal clock and the
external environment result in severe health consequences, such as shift work disorder,
increased risk for metabolic syndrome, and increased risk for certain cancers (reviewed
in: (Bass & Takahashi, 2010; Gamble et al., 2014; Silver & Kriegsfeld, 2014; Man et al.,
2016)).
Three characteristics distinguish circadian rhythms from other biological
oscillations. First, circadian rhythms cycle endogenously in the absence of environmental
input. In constant conditions, they cycle with an approximately 24 h period, a state known
as free-running. Second, they are temperature compensated, meaning the period remains
constant in a variety of physiologically relevant temperatures.

And finally, circadian

rhythms can synchronize to the environment, a process known as entrainment, by
responding to environmental stimuli with a period close to 24 h that act as zeitgebers
(Aschoff, 1960), or “time-givers.” Light serves as the dominant zeitgeber for most species,
providing input that locks the endogenous clock to the daily light/dark cycle (reviewed in
(Chaix et al., 2016; Hurley et al., 2016; Herzog et al., 2017).
In mammals, circadian rhythms are governed by a central circadian pacemaker,
located in the suprachiasmatic nucleus (SCN) of the hypothalamus in the brain (Gamble
et al., 2014; Silver & Kriegsfeld, 2014; Bass & Lazar, 2016; Cribbet et al., 2016). The SCN
is a bilateral structure comprised of densely packed neurons and astroglial cells located
dorsal to the optic chiasm, straddling the third ventricle. Most SCN neurons release the
2

neurotransmitter gamma-Aminobutyric acid (GABA), but the SCN is quite heterogeneous,
and can broadly be divided into the retinorecipient gastrin-releasing peptide (GRP) and
vasoactive intestinal peptide (VIP) expressing ventrolateral core and vasopressin (AVP)
expressing dorsomedial shell (Hattar et al., 2006; McNeill et al., 2011; Mohawk &
Takahashi, 2011; Herzog et al., 2017). An elegant series of studies defined the SCN as
the master circadian pacemaker. Early work suggested the clock may be found in the
hypothalamus (Richter, 1965), followed by identifying the SCN as the terminal point for
the RHT (Hendrickson et al., 1972; Moore & Eichler, 1972; Moore & Lenn, 1972; Moore,
1973). SCN lesion studies demonstrated that ablation of the SCN eliminates circadian
rhythms (Moore & Eichler, 1972; Stephan & Zucker, 1972; Rusak, 1979). Metabolic
imaging and electrophysiology demonstrated that the SCN exhibits circadian rhythms in
vivo (Inouye & Kawamura, 1979), and 2-deoxyglucose (2-DG) radiolabeled imaging
(Schwartz & Gainer, 1977) and electrophysiology on SCN brain slices demonstrated that
the SCN retains this rhythmicity in vitro (Green & Gillette, 1982; Groos & Hendriks, 1982;
Shibata et al., 1982). The strongest support of the SCN as the primary pacemaker came
from studies demonstrating that transplantation of fetal SCN grafts into the brains of SCN
ablated animals restores circadian rhythms, with a period identical to that of the host
(Drucker-Colin et al., 1984; Sawaki et al., 1984; DeCoursey & Buggy, 1989). Finally, SCN
cell culture studies demonstrated that circadian rhythms are cell autonomous (Welsh et
al., 1995).
The current model for the SCN circadian oscillator consists of a cell autonomous
transcriptional-translational-posttranslational negative feedback loop (TTFL) involving a
group of clock genes that includes Period (Per) 1 and 2; Cryptochrome (Cry) 1 and
2, Bmal1, and Clock (Reviews:(Hardin, 2004; Gallego & Virshup, 2007; Buhr & Takahashi,
2013; Hastings et al., 2014). BMAL1 and CLOCK proteins are transcriptional activators
that act as a heterodimer to increase transcription of Per and Cry (Vitaterna et al., 1994;
Reppert & Weaver, 2002). PER and CRY proteins accumulate in the cytoplasm, until they
reach a critical level where PER and CRY proteins enter the nucleus, dimerize, and inhibit
the activity of BMAL1/CLOCK. This suppresses Per and Cry transcription, and once PER
and CRY levels decrease the cycle restarts. Phosphorylation of PER proteins leads
to their degradation, which slows the rate of accumulation. Additional regulators of this
core mechanism, including a redox oscillator and a cell membrane oscillator, are thought
3

to strengthen and stabilize the SCN circadian clock (Gillette & Wang, 2014; Hastings et
al., 2014; Milev et al., 2015). The TTFL is found in every cell in the body, and it acts as
the gears of the clock, generating and maintaining a ~24 h cycle. In the SCN, the rhythms
of individual cells are coordinated to one another, then entrained to the environment, and
the phase from the SCN is distributed to the remainder of the body.
Several stimuli can entrain the clock, creating a period equal to the entraining
cycle. These include food availability (Edmonds & Adler, 1977), social contact (Mrosovsky,
1988; Mrosovsky et al., 2005), temperature, moonlight (Neumann, 1989; FernandezDuque & Erkert, 2006), or tides (a unique case allowing 24 h entrainment to an
approximately 12 h input) (Palmer, 2000).

However, light signals are the dominant

synchronizing signal (Czeisler, 1995). The SCN receives input from the retina,
intergeniculate leaflet (IGL), and raphe nuclei, but retinal signals are the primary source
of photic phase-resetting information. Light pulses during subjective night or transitions
from light to dark at subjective dawn or dusk shift the clock phase (Daan, 1977; Johnson,
1999; Johnson et al., 2003; Roenneberg et al., 2003). Depending on the time of day,
phase shifts can either result in a shift forward or a fall back in clock timing. Light
stimulates melanopsin containing retinal ganglion cells to release neurotransmitters
(Johnson et al., 1989; Berson et al., 2002), including glutamate (Ebling, 1996; Hannibal,
2002), pituitary adenylate cyclase-activating peptide (PACAP) (Hannibal, 2006), and
substance P onto SCN neurons (Chen et al., 1999; Golombek et al., 2003; Fahrenkrug,
2006; Hannibal, 2006). Of these, several lines of evidence support glutamate as the
primary photic signal (Ding et al., 1994; Golombek & Rosenstein, 2010; Welsh et al.,
2010).

The

SCN

contains α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic

acid

receptors (AMPAR) and N-Methyl-D-aspartic acid receptors (NMDAR), but only NMDAR
stimulation replicates phase shifting (Colwell & Menaker, 1992; Vindlacheruvu et al., 1992;
Gannon & Rea, 1993; Ding et al., 1994; Gannon & Rea, 1994; Shirakawa & Moore, 1994b;
a). Blocking NMDARs prevents phase shifts, suggesting that NMDARs are the primary
source of glutamatergic phase shifting signals in the SCN (Ding et al., 1994). Activation
of NMDARs results in a calcium influx (Ding et al., 1998; Obrietan et al., 1998; Colwell,
2000; 2001), which through the activation of a variety of downstream effectors (discussed
below) results in a phase shift. Importantly, phase shifting only occurs when these events
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happen during the subjective night-time, and not during the subjective day (Meijer &
Schwartz, 2003; Cheng & Obrietan, 2006; Colwell, 2011).
The intracellular molecular mechanisms linking light stimuli to phase shifts are not
fully elucidated, but several downstream effectors and signaling cascades have been
demonstrated to play a role. A variety of kinases are activated following the NMDAR
calcium influx. An early effect is activation of Ca2+/calmodulin-dependent protein kinase
II (CaMKII) by autophosphorylation on Thr286/287 (Fukushima et al., 1997; Yokota et al.,
2001; Golombek et al., 2004).

Increases in p(hosphorylated)CaMKII result in

phosphorylation of neuronal nitric oxide synthase (nNOS), causing nitric oxide (NO)
production (Agostino et al., 2004). Downstream of NO production the process of phase
shifting bifurcates (Golombek et al., 2004). In the early night, phase delays require
calcium-induced calcium release from ryanodine receptors (RyRs) (Ding et al., 1998). In
the late night, NO activates guanylate cyclase (GC) and increases cyclic guanosine
monophosphate (cGMP) (effects that do not happen in the early night), resulting in a
phase advance (Weber et al., 1995; Ding et al., 1998; Prosser, 1998b; Tischkau et al.,
2003). The phase delaying and phase advancing pathways re-converge, and there is a
transient rapid phosphorylation of cAMP response element binding protein (CREB), that
ultimately causes transcription of Per and other cAMP response element (CRE) regulated
genes, effectively resetting the clock phase (Ginty et al., 1993; Ding et al., 1997; Gau et
al., 2002). Also involved are mitogen-activated protein kinase (MAPK) and protein kinase
A (PKA), but their link to entrainment isn’t well understood (Obrietan et al., 1998; Tischkau
et al., 2000; Butcher et al., 2002; Antoun et al., 2012). Light-induced phase shifts can be
mimicked in vitro by application of glutamate to SCN brain slices (Golombek & Rosenstein,
2010; Iyer et al., 2014; Cooper, Submitted). In vivo phase shifts can be assessed by
observing behavioral patterns, and in vitro phase shifts can be assessed by observing a
variety of clock outputs, including rhythmic clock gene expression and neuronal activity
patterns.
The intracellular oscillatory mechanisms described above create an elegant
pacemaker model, but they do not fully account for several important SCN functions
including synchronization and entrainment.

Accumulating evidence suggests that

extracellular molecules contribute to these processes. Intercellular coupling mechanisms
within the SCN synchronize the individual cell’s rhythms to one another, and recent
5

evidence highlights an important role for astrocytes in maintaining SCN synchrony (Evans,
2016; Herzog et al., 2017). A variety of extracellular molecules are implicated in the
process of phase shifting, including extracellular proteases and cell adhesion molecules
such as neural cell adhesion molecule (NCAM), L1 cell adhesion molecule (L1-CAM),
neurexins and neuroligins, Eph-ephrins, and integrins (Prosser et al., 2003; Mou et al.,
2009b; Cooper, Submitted).

Many of these extracellular molecules overlap with

interactions on the extracellular matrix (ECM), which acts as a critical regulator of synaptic
connections (Song & Dityatev, 2018). Many extracellular molecules also have astrocytic
roles. The precise mechanisms through which all of these molecules work have not been
fully elucidated yet, but it is apparent that changes in the extracellular space exert dramatic
influence over the timekeeping mechanisms.
1.1.2

Neuronal plasticity in the SCN – daily rhythms in neuronal responses to
glutamate
One particularly intriguing phenomenon in the SCN is a dramatic duality in

responses to glutamate over the course of the day. Neuroplasticity refers to the ability of
stimuli to induce structural and functional changes in neuronal responses. It is most
thoroughly studied in terms of long term potentiation (LTP) and long term depression
(LTD) in the hippocampus, where different patterns of neuronal stimulation induce either
exaggerated (LTP) or attenuated (LTD) responses to subsequent stimuli (Malenka & Bear,
2004). The SCN exhibits a unique case of circadian plasticity where the response to a
stimulus (light/glutamate), differs depending on the time of day that stimulus is presented
(Iyer et al., 2014). As mentioned above, glutamate (or light) induces phase shifts at night,
but not day, which means there is an endogenous rhythm in the neuronal responsiveness
in the SCN (Iyer et al., 2014). This is further complicated by the divergent direction of shift
in the early night vs late night. This suggests that there are persistent changes in synaptic
connections that occur on a 24 h cycle, allowing for these cycles in neuronal
responsiveness (Iyer et al., 2014). While much remains unclear about the mechanisms
underlying this phenomenon, termed “daily iterative metaplasticity,” it is apparent that the
mechanisms that influence neuronal plasticity in other systems, particularly the
hippocampus, often have a conserved function of gating phase shifting in the SCN (Iyer
et al., 2014). Some events that contribute to this daily plasticity include rhythms in
6

membrane potential, expression of proteins that influence neuroplasticity, and
expression/functional status of intracellular signaling molecules (Iyer et al., 2014).
An important mediator of glutamate-induced phases shifts, NMDARs, are
intricately associated with neuronal plasticity, and changes in their expression patterns,
subunit composition, cell surface localization, and interacting partners can dramatically
alter neuronal responses (Hunt & Castillo, 2012). NMDARs are heteromeric complexes
containing four subunits generally composed of two obligate NR1 subunits complexed with
a combination of NR2 (A-D) or NR3 (A-B) subunits (Moriyoshi et al., 1991; Traynelis et al.,
2010; Paoletti et al., 2013; Iacobucci & Popescu, 2017). NMDAR subunit composition and
phosphorylation patterns can influence their localization and activity patterns. NMDARs
exhibit distinct diurnal rhythms in the SCN, with mRNA of ɛ3 (also known as NR2A) and
ζ1 (NMDAR1) high during the day and low at night in rats, with anti-phase patterns in their
respective proteins (Ishida et al., 1994). Expression of those two NMDARs also increases
in response to light stimulation in the subjective night (Ishida et al., 1994). Expression and
phosphorylation of NR2A and NR2B protein exhibits circadian rhythms in hamster SCN,
with phosphorylated NR2B peaking in the late night (Wang et al., 2008). There are also
endogenous rhythms in magnitude and duration of NMDAR calcium transients in SCN,
which peak during the night, as does a rhythm in NMDAR-evoked currents (Pennartz et
al., 2001). Collectively, these data suggest that NMDAR function peaks at night, which
could allow increased responsiveness to glutamate.

However, quite a bit remains

unknown about actions of NMDARs as gating molecules in the SCN, and importantly,
changes in cell surface localization and potential modulators of NMDAR function remain
largely un-investigated.
Growth factors also contribute to the diurnal responses.

Brain-derived

neurotrophic factor (BDNF) is a secreted neurotrophin that regulates neuronal signaling
across the central nervous system (CNS), and is important for a variety of neuroplastic
events (Kowianski et al., 2018). BDNF exerts its function by binding to neurotrophin
receptors, p75 and tyrosine kinase B receptors (TrkB) (Reichardt, 2006). In the nervous
system, BDNF binding to TrkB is important for many of its effects on neuroplasticity. BNDF
binding induces TrkB autophosphorylation, which activates a variety of protein kinases
(Chao & Hempstead, 1995; Reichardt, 2006). BDNF is transcribed as an ~32 kDa
proBDNF that is cleaved into ~14 kDa m(ature) BDNF, which is the form that binds TrkB
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receptors (Foltran & Diaz, 2016). In the SCN, BDNF levels are rhythmic – they are high
at night and low during the day (Liang et al., 1998). At night, these high levels of BDNF
enable it to bind TrkB receptor, which in other regions can stimulate concurrent
phosphorylation of NR1 NMDAR subunits (Slack et al., 2004) and in the SCN enables
glutamate-induced phase shifts (Liang et al., 2000; Allen et al., 2005; Mou et al., 2009b).
Inhibiting TrkB receptors or decreasing BDNF expression disrupts SCN responses to
glutamate (Allen et al., 2005). Collectively, it seems that BDNF and TrkB receptors are
key molecules acting to gate phase shifts, but similar to NMDARs, many questions still
remain. In particular, we do not fully understand how they are regulated and respond to
daily changes in the SCN.
The gating of photic phase resetting also involves intracellular signaling events,
including the actions of cAMP. In the rat SCN, there are spontaneous oscillations in cAMP
levels and cAMP-dependent protein kinase (PKA) activity (Prosser & Gillette, 1991).
cAMP levels peak at the end of the day and the night, which corresponds to the day/night
transitions (Prosser & Gillette, 1991). cAMP levels also increase in response to light or
glutamate stimulation, but application of cAMP agonists does not mimic the phase shifting
effects of light or glutamate stimulation (Tischkau et al., 2000). Concurrent activation of
cAMP/PKA with light or glutamate results in enhanced phase shifts during the early night,
but diminished phase shifts in the late night (Tischkau et al., 2000). Thus, the cAMP/PKA
system may alter the baseline status of cell signaling pathways based on time of activation,
resulting in opposing responses at different times (Tischkau et al., 2000). Similar changes
in other intracellular effectors may also participate in gating photic phase shifts, but the
molecules controlling their diurnal variations have not been elucidated.
In general, the circadian oscillator sets the cellular stage such that it is more
responsive to photic stimuli at night than during the day (Iyer et al., 2014). As discussed
above, several signaling molecules are known to be under circadian control, but these
changes pale when compared to the complex picture of neuronal synaptic plasticity
generally. Strengthening and weakening synaptic connections involves growth factors
and their direct downstream effectors, changes in receptor expression, localization, and
activation status, differences in astrocytic clearance of neurotransmitters from the
synapse, adjustments in synaptic morphology, and ECM reorganization. Importantly,
there is evidence that similar plasticity events may be happening in the SCN, particularly
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with response to ECM changes. For example, there is evidence that a variety of ECMassociated proteins, such as cell adhesion molecules (CAMs) and extracellular proteases,
are involved in circadian clock phase regulation (Cooper, Submitted). There are also data
suggesting that the ECM may be important for daily changes in synaptic ultrastructure,
which may be important for gating photic signals. There are day/night variations in glial
and axonal terminal coverage on VIP neurons: during the night glia tightly surround VIP
dendrites and are retracted from AVP dendrites, while in the day-time they move to cover
AVP dendrites more closely and retract from VIP dendrites (Becquet et al., 2008; Girardet
et al., 2010). Similar changes in other brain regions are restricted by the presence of the
ECM and enabled following ECM remodeling. As summarized below, we have started
identifying a few extracellular modulators of glutamate signals in the SCN, but much
remains unknown about how the SCN achieves the day-night duality of responses.

1.2 The Plasminogen Activators
One particularly interesting group of proteins that modulates neuronal activity are
extracellular proteases. A variety of secreted proteases exert dramatic influence over
neuronal processing by cleaving ECM molecules, cell adhesion molecules, and growth
factors, as well as through both proteolytic and non-proteolytic interactions with cell
surface molecules (Salazar et al., 2016). These actions can facilitate structural changes
in the extracellular space, change the strength of synapses, have direct effects on
neurotransmitter receptors, and act as signaling events, all of which serve to mediate
changes in cellular responses as a consequence of changes in the extracellular space
(Salazar et al., 2016). The plasminogen activators, tissue-type plasminogen activator
(tPA) and urokinase plasminogen activator (uPA), are extracellular proteases that
modulate a variety of neuronal processes, and with particular relevance to circadian clock
phase shifting, they have been found to influence glutamatergic signaling.
tPA and uPA are serine proteases whose primary function is to cleave
plasminogen into proteolytically active plasmin. tPA was identified in the vascular system
for its role in dissolving fibrin blood clots, while uPA was originally found in the urinary
tract. The plasminogen activators have overlapping and divergent functions and partners
(Camiolo et al., 1971; Collen & Lijnen, 1991). Their activity is modified by inhibitors and
interacting proteins, and they cleave a variety of downstream targets (Al-Horani, 2014).
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tPA is secreted in a pro form, which can be cleaved by plasmin into a two-chain form
(Chevilley et al., 2015). Both forms of tPA are proteolytically active, but differ in stability
and targets (Chevilley et al., 2015).

tPA activity is inhibited by two main inhibitors,

plasminogen activator inhibitor 1 (PAI-1), which requires an interacting partner, vitronectin
(VN), and neuroserpin, which is the primary inhibitor found in the brain (Al-Horani, 2014).
tPA also interacts with several membrane-associated proteins, including low density
lipoprotein-receptor related protein 1 (LRP-1) and annexin II (Archinti et al., 2011;
Chevilley et al., 2015).

Aside from activating plasminogen, tPA also cleaves ECM

molecules, matrix metalloproteinases (MMPs), and CAMs (Archinti et al., 2011). uPA is
also secreted in a single chain pro-form, but it remains inactive until it is cleaved by plasmin
into the active two-chain form upon binding to its receptor, uPA receptor (uPAR) (Lijnen
et al., 1987a). Similar to tPA, uPA is also inhibited by PAI-1 and neuroserpin, interacts
with LRP-1 and annexin II, and it’s activity can affect ECM molecules, including MMPs
and CAMs (Ishida et al., 1994; Archinti et al., 2011; Chevilley et al., 2015).
1.2.1

tPA regulates glutamate signaling in the brain
Early work suggested fibrinolytic activity occurs in the brain, and eventually

supported tPA expression in the central nervous system (Fantl & Fitzpatrick, 1950;
Takashima et al., 1969; Tovi, 1973; Krystosek & Seeds, 1981; Soreq & Miskin, 1981;
Basham & Seeds, 2001).

We now know that tPA, uPA, PAI-1, neuroserpin, and

plasminogen are expressed in the brain and can be found in neurons and astrocytes of
many regions, including the cortex, limbic system, hypothalamus, and cerebellum
(Kalderon et al., 1990; Presta et al., 1990; Masos & Miskin, 1996; Lee et al., 2017).
Subsequent research, discussed below, has demonstrated that the plasminogen
activators and their interacting partners are potent regulators of neuroplasticity throughout
the central nervous system.
tPA has received much attention for its diverse and complex roles in regulating
neuronal processes. tPA is abundantly expressed in the brain, and can be found in
endothelial cells (Sappino et al., 1993), glial cells (Siao et al., 2003), and neurons (Nicole
et al., 2001; Yepes et al., 2009). In neurons tPA can be localized to synaptosomes
(Zisapel et al., 1982). tPA expression is also inducible in the brain, and it has been
identified as one of 5 immediate-early genes induced following seizure or high frequency
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stimulation, suggesting tPA could modulate “structural changes that accompany activitydependent plasticity” (Qian et al., 1993). tPA has been associated with many functions of
the brain, including cell migration, neurite growth, cell-cell adhesion, synaptic plasticity,
neurodegeneration, neuroprotection, neurovascular permeability, and Alzheimer’s
disease (Lee et al., 2015). The mechanisms through which tPA functions are equally
diverse. In some cases, tPA acts through plasmin-dependent functions. In other cases,
tPA proteolytic activity that is independent of plasmin generation is important. Additionally,
tPA can act through non-proteolytic mechanisms that often involve interactions with
specific receptors, including annexin II, LRP-1, or NMDAR. (Qian et al., 1993; Madani et
al., 1999; Oray et al., 2004; Yepes et al., 2016).
Evidence supporting a role for tPA in neuroplasticity comes from studies identifying
involvement of tPA in LTP and LTD (Baranes et al., 1998; Fiumelli et al., 1999; Pang &
Lu, 2004; Pang et al., 2004; Salazar et al., 2016; Medcalf, 2017). There are deficits in LTP
in tPA knockout mice, and increases in LTP when tPA is over-expressed (Baranes et al.,
1998; Pawlak et al., 2002).

tPA enhances hippocampal learning, LTP, and LTP-

associated synapse formation, and these effects are inhibited by PAI-1 (Baranes et al.,
1998). tPA is also implicated in various non-hippocampal learning and memory paradigms
(Melchor & Strickland, 2005). One mechanism through which tPA influences neuronal
activity is by activating BDNF downstream of plasmin generation (Fiumelli et al., 1999;
Pang & Lu, 2004; Pang et al., 2004).

As discussed before, BDNF activation

of TrkB influences neuronal responses to a variety of stimuli, and it also results in an
increase in tPA expression (Kuzniewska et al., 2013). This creates the potential for a
positive

feed-forward

loop

that

serves

to

increase

tPA-dependent

events.

tPA, plasminogen, and pro-BDNF are co-localized within dense core granules of
embryonic rat hippocampal neurons, these vesicles are transported preferentially to
active dendritic spines, and the three proteins are co-secreted in response to LTPinducing stimulation (Lochner et al., 2008). Thus, tPA modulation of BDNF signaling may
be important for tPA-dependent effects on neuroplasticity throughout the brain.
Apart from activating BDNF, tPA has additional signaling targets in the brain. For
example, tPA interacts with NMDAR NR1 and NR2B subunits and influences NMDAR
signaling through a process that may involve plasmin-independent proteolytic cleavage of
NR1, as well as through cleaving NR2A subunits via plasmin (Yuan et al., 2009; Ng et al.,
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2012; Obiang et al., 2012). These actions affect NMDAR signaling, and generally act to
increase the responsiveness and/or calcium influx in response to glutamate stimulation
(Pawlak et al., 2005a; Pawlak et al., 2005b; Norris & Strickland, 2007), though tPA has
been found to decrease responses to low NMDA concentrations in hippocampal neurons
(Martin et al., 2008). tPA’s interactions with other receptors, including LRP-1 (discussed
below), also contribute to hippocampal LTP (Zhuo et al., 2000). Another tPA-binding
receptor, annexin II, is widely expressed throughout the brain, particularly in endothelial
cells, and is thought to increase plasmin generation following tPA treatments (Kang et al.,
1999; Zhao & Lu, 2007).

Binding to these receptors can restrict tPA’s sphere of

activity and modify its proteolytic activity, potentially serving as a co-receptor to increase
proteolytic efficiency (Miles & Parmer, 2013; Chevilley et al., 2015). tPA interactions with
growth factor pathways, such as interactions with epidermal growth factor receptor
(EGFR) and platelet-derived growth factor (PDGF) also influence neuronal function (Zhuo
et al., 2000; Miles & Parmer, 2013; Chevilley et al., 2015; Lemarchand et al., 2016).
Collectively, through a combination of mechanisms, tPA modulates neuronal responses
to such an extent that it has been characterized as a neuromodulator and potentially a
gliotransmitter (Casse et al., 2012b).
1.2.2

uPA influences neuronal processes
uPA has not received as much attention as tPA in the central nervous system, but

it also participates in synaptic remodeling, particularly during development and following
injury (Merino et al., 2017a). uPA and uPAR are highly expressed in the CNS during
development, and can be found in neurons, microglia, and astrocytes (Cho et al., 2012;
Wu et al., 2014; Merino et al., 2017a). uPA and uPAR levels are very low in the adult
brain, but they increase following injury (Wu et al., 2014). uPA, uPAR, and LRP-1 are
rapidly upregulated following spinal cord hemisection, followed by an increase in tPA
(Seeds et al., 2009). uPA acting via uPAR is necessary for post-hemisection remodeling
(Seeds et al., 2009).

Additionally, following ischemic stroke, uPA-uPAR signaling

enhances dendritic spine recovery in cortical neurons (Wu et al., 2014). The evidence
supports a model where neurons release uPA following oxygen glucose deprivation, which
binds astrocytic uPAR to allow synaptic recovery (Diaz et al., 2017). In this system, uPA
may be acting to activate astrocytes, as uPA induces GFAP expression (a marker of
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astrocytic activation) in wildtype but not uPAR knockout mice (Diaz et al., 2017). uPA has
also been reported to cleave NR1 and NR2B subunits to alter NMDAR signaling (Ng et
al., 2012). uPAR knockout mice exhibit disrupted neuronal networks, with fewer cortical
GABAergic interneurons, increased seizures, enhanced anxiety, and decreased social
interactions (Powell et al., 2003; Eagleson et al., 2005; Ndode-Ekane & Pitkanen, 2013;
Wu et al., 2014; Rantala et al., 2015). uPAR interacts with cell-surface proteins, including
LRP-1, integrins, and receptor tyrosine kinases, and these interactions often mediate
internalization of the receptor-protein-ligand complex (Madsen et al., 2007; Miles &
Parmer, 2013; Van Gool et al., 2015). Although uPA has not been investigated as
extensively as tPA in regards to neuronal processes, it has been well studied in the context
of cancer, including glioblastoma, and mechanistic insights from pathological situations
may provide clues to its physiological roles (Mohanam et al., 1994; Rustamzadeh et al.,
2003). It is important to note that while current evidence implicates tPA as a modulator of
neuroplasticity and focuses on uPA in the context of injury response, we cannot assume
that they don’t overlap in these functions. Indeed, one protease may compensate for the
other in a variety of contexts, and untangling the associations and differences between
the two will be important to our understanding of the plasminogen activators.
1.2.3

tPA regulates glutamate-induced phase shifts
Because of the overlap between tPA’s role in the CNS and processes already

known to gate glutamate-induced phase shifting, particularly regarding BDNF maturation,
our lab undertook a study of tPA in the mammalian SCN (Mou et al., 2009b). We found
that tPA contributes to the processes regulating glutamate-induced phase shifting of the
SCN circadian clock in vitro, identifying a new role for plasminogen activators in the brain.
Members of the plasminogen activating cascade, including PAI-1, VN, tPA, plasminogen,
plasmin, mBDNF, and proBDNF, are all expressed in the SCN (Mou et al., 2009b). tPA,
plasmin, and mBDNF expression exhibit diurnal rhythms, with higher levels at night than
during the day, while PAI-1 exhibits an inverse rhythm with high daytime expression (Mou,
2010; Cooper et al., 2017). Treating SCN slices in vitro with PAI-1 blocks glutamateinduced phase delays at ZT16 and phase advances at ZT23, indicating that tPA proteolytic
activity is necessary for these phase shifts (Mou et al., 2009b). Additional evidence
supports a role for tPA acting upstream of BDNF to gate clock phase shifts: inhibiting
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plasmin with α2-antiplasmin blocks glutamate-induced phase shifts, and co-application of
plasmin or mBDNF but not plasminogen recover phase shifting (Mou et al., 2009b).
Vitronectin is also necessary for PAI-1’s actions in the SCN, as PAI-1 does not block phase
shifts in vitronectin knockout mice (Mou et al., 2009b). Collectively, this suggests that at
night, when tPA levels are highest, it converts plasminogen into plasmin, which then
cleaves proBDNF into mBDNF, which binds to TrkB receptors enabling glutamate-induced
phase shifts (Mou et al., 2009b).
Glutamate-induced changes in tPA expression could contribute to tPA’s role in
phase shifting, and thus Mou and colleagues also investigated changes in protein
expression following glutamate treatment (Mou, 2010). Glutamate application to in vitro
SCN slices increases tPA levels in the early night, but not in the late night or mid-day.
This glutamate treatment does not alter PAI-1, plasmin, or BDNF levels (Mou, 2010).
Treating SCN slices with glutamate and PAI-1 concurrently causes a reduction in plasmin,
while concurrent glutamate and α2-antiplasmin reduces pro- and mBDNF levels (Mou,
2010). And finally, mBDNF levels are lower in tPA knockout (tPA-/-) mice when compared
to wild-type (WT), supporting tPA as a mediator of BDNF maturation (Mou, 2010).
Collectively these data generally support the model described above. However, a couple
of discrepancies suggest that tPA’s role in the SCN may be more complex. First, the
glutamate-induced increase in tPA expression in the early night but not in the late night
are at odds with the finding that PAI-1 prevents phase shifts at both times, which may
mean there are mechanistic differences between early and late night phase shifts.
Second, it is interesting that α2-antiplasmin reduces both pro- and mBDNF levels, as this
suggests it is regulating total BDNF expression rather than just BDNF maturation.
This work defined a role for tPA acting upstream of mBDNF to gate glutamate
phase resetting responses in the SCN, but also created a variety of questions. This study
did not investigate circadian phase shifting in tPA knockout mice either in vivo or in vitro.
Whether or not uPA is involved in circadian clock phase regulation also was not
addressed.

Additionally, tPA does not work in isolation, and some key potential

contributors to tPA function in the SCN remained uninvestigated. In particular, LRP-1
mediates a variety of tPA-dependent functions in the brain and periphery, and therefore
could be influencing the circadian clock. tPA has also been reported to modulate neuronal
signaling through direct interactions with NMDARs, and this possibility was not
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investigated with respect to SCN clock phase regulation. The work presented here
addresses these knowledge gaps in two ways. First, we assessed SCN phase shifting in
tPA-/- mice, and uncovered an unexpected role for uPA in regulating clock phase shifting.
Second, we investigated LRP-1 as a potential modulator of SCN phase shifts, with a
specific focus on interactions between LRP-1, tPA, and NMDARs. My aims were twofold:
first, to increase our understanding of how extracellular molecules influence synaptic
plasticity in the SCN by continuing our investigation of extracellular proteases; and
second, to investigate the closely associated membrane receptor, LRP-1, whose activity
is associated with transducing information regarding the extracellular space and
responding to changes in ligands by mediating their endocytosis and/or activating signal
transduction. Together, this research furthers our understanding of the mechanisms
gating SCN circadian clock phase shifting, and simultaneously advances our knowledge
of how this group of extracellular synaptic plasticity modulators functions in the brain.

1.3 Low-density lipoprotein receptor-related protein-1
1.3.1

LRP-1 introduction
LRP-1, a member of the low-density lipoprotein (LDL) receptor family, is a large

membrane receptor that is widely expressed in many tissues. LRP-1 is 600 kDa protein
composed of a 515 kDa extracellular αLRP-1 subunit that is non-covalently associated
with an 85 kDa transmembrane βLRP-1 subunit (Kerrisk et al., 2014; Ramanathan et al.,
2015).

The αLRP-1 subunit contains cysteine-rich complement-type ligand binding

repeats, and epidermal growth factor (EGF) repeats and β-propeller domains that function
in the release of ligands (Lillis et al., 2005). The βLRP-1 subunit contains a single
transmembrane domain and cytoplasmic domain, which has two NPxY motifs that can be
phosphorylated to contribute to endocytosis and signal transduction (Lillis et al., 2005).
Additionally, the extracellular subunit can be “shed” via metalloproteinase cleavage on the
β subunit, generating a soluble protein whose function isn’t entirely understood, but may
serve to sequester and inactivate LRP-1 ligands in the extracellular space (Van Gool et
al., 2015).
LRP-1 is a highly efficient transport protein, which binds over 50 different ligands
extracellularly, and can mediate rapid endocytosis or influence signal transduction
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following ligand binding (Lillis et al., 2005). Through these functions, it regulates a variety
of physiological processes, including lipoprotein metabolism, protease degradation,
lysosomal enzyme activation, and cellular entry of bacterial toxins and viruses (Lillis et al.,
2008). LRP-1 ligands are diverse, and include APO-E, tumor growth factor-β, MMP’s,
neuroserpin, tPA, uPA, and amyloid-β (Lillis et al., 2005). LRP-1 also interacts with a
variety of cytoplasmic adaptor proteins in a phosphorylation-specific manner, and can
modulate activity of transmembrane receptors such as integrins and receptor tyrosine
kinases (Lillis et al., 2005). Regulation of signal transduction is often coupled with other
cell surface receptors such as PDGF receptor (PDGFR) and leptin receptors, and
mediated via intracellular kinases (Muratoglu et al., 2010; Liu et al., 2011; Strickland et al.,
2014). Interactions with other receptors, including uPARs and NMDARs have also been
show to mediate LRP-1 dependent effects (Lillis et al., 2005; Ramanathan et al., 2015;
Van Gool et al., 2015).
1.3.2

LRP-1 regulates neuroplasticity throughout the brain
LRP-1 is abundantly expressed in the central nervous system, where it can be

found on vascular smooth muscle cells, pericytes, astrocytes, and neurons (Lillis et al.,
2008; Shinohara et al., 2017). Deletion of the Lrp1 gene is embryonically lethal, indicating
a critical involvement in development (Lillis et al., 2008; Liu et al., 2010). Neuronal specific
deletion of Lrp1 in mice results in severe behavioral and motor abnormalities, including
hyperactivity, tremor, and dystonia (May et al., 2004). LRP-1 protein can be expressed in
the post synapse, where it regulates synaptic integrity, partly through regulating glutamate
receptors (May et al., 2004).
tPA is a prominent LRP-1 ligand, and tPA binding to LRP-1 activates LRP-1
dependent signaling in a variety of contexts (Zhuo et al., 2000; Yepes et al., 2003; Samson
et al., 2008; Echeverry et al., 2010). In rat kidney interstitial fibroblasts, tPA acts as a
cytokine by binding to LRP-1, inducing tyrosine phosphorylation on LRP-1’s intracellular
domain, and triggering signal transduction that is able to induce specific gene expression,
including Mmp9 expression (Hu et al., 2006). In this system, tPA stimulates extracellular
signal–regulated kinases (ERK1/2) phosphorylation to protect against apoptosis, and
LRP-1 is required for these events (Hu et al., 2008). tPA can also stimulate ERK1/2
activity in hippocampal neuronal cell culture, and LRP-1 is necessary for this event (Martin
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et al., 2008). The results of this study support tPA, NMDAR, and LRP-1 acting in complex
to mediate tPA-dependent effects, and identified the distal NPxY motif on LRP-1 as a key
mediator of the LRP-1/NMDAR interaction (Martin et al., 2008). Additionally, LRP-1
mediates the LTP-enhancing effect of tPA in tPA-/- hippocampal slices (Zhuo et al., 2000).
LRP-1 is also required for tPA-mediated microglial activation in the central nervous system
(CNS) following middle cerebral artery occlusion (MCAO; a model of brain
ischemia/stroke) (Zhang et al., 2009b).

tPA increases MMP-1 expression following

MCAO, and this also depends on the presence of LRP-1 (Zhang et al., 2009a). In cultured
Schwann cells LRP-1 functions as an injury detection receptor by inducing c-Jun
phosphorylation downstream of tPA binding (Flutsch et al., 2016). Astrocytic-derived tPA
induces astrocytic outgrowth via LRP-1-dependent induction of ERK activity (Qian et al.,
2016). tPA and LRP-1 have complementary effects on lipopolysaccharide (LPS)-induced
inflammation, where tPA inhibits LPS induced inflammation through a pathway that
involves LRP-1 (Mantuano et al., 2017).

Collectively, these studies are consistent with

the idea that tPA binding to LRP-1 can initiate a variety of signaling events. In addition to
its signaling responses, LRP-1 can mediate the clearance of tPA by transporting tPA
across the blood-brain barrier (Benchenane et al., 2005). LRP-1 also contributes to tPA
recycling in the nervous system (Casse et al., 2012b): glutamate induces LRP-1
dependent astrocytic endocytosis and recycling of tPA (Casse et al., 2012b). And finally,
there is evidence that LRP-1 may act as a co-receptor, increasing tPA proteolytic activity,
as it does for tPA-mediated cleavage of platelet derived growth factor-CC (PDGFR-CC)
(Su et al., 2017). Thus, the interactions between tPA and LRP-1 in the nervous system
are complex and multifunctional.
LRP-1 can also modulate neuronal activity through its association with NMDA
receptors. LRP-1 physically interacts with NMDAR via binding to postsynaptic density
protein 95 (PSD95) (May et al., 2004), allowing it to control NMDAR trafficking and
degradation, and thus NMDAR surface localization (Maier et al., 2013). LRP-1 modulates
neuronal calcium signaling via NMDAR (Bacskai et al., 2000).

LRP-1’s intracellular

domain can regulate NMDAR-mediated signaling processes (Nakajima 2013), and LRP1 can form complexes with Trk receptors to modulate NMDAR signaling (Mantuano et al.,
2013). As mentioned above, LRP-1 may also influence NMDAR signaling by regulating
the activity of tPA (Casse et al., 2012b). Separately, LRP-1 can influence neuronal
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plasticity through interactions AMPA receptors. LRP-1 has been found to influence the
trafficking, phosphorylation, and turnover of GluA1 subunits of AMPA receptors (Gan et
al., 2014). One final association worth mentioning involves interactions between LRP-1
and amyloid precursor protein (APP). LRP-1 binds and mediates cellular catabolism of
longer forms of APP (Kounnas et al., 1995), and internalizes transmembrane isoforms of
APP (Knauer et al., 1996). LRP-1 mediated internalization of both soluble and membrane
forms of APP may lead to changes in neuronal activity. In general, it seems that in addition
to its endocytic and signaling activities, LRP-1 functions to regulate surface localization of
a variety of membrane receptors.
1.3.3

LRP-1 overlaps with mechanisms that gate phase shifts
LRP-1 acts as a sensor and regulator of the extracellular space, and responds to

extracellular changes in ways that modulate neuronal responses. The aforementioned
functions of LRP-1 all intersect with processes known to gate SCN clock phase shifting,
and in particular they influence responses to glutamate signals. LRP-1 regulates and
responds to extracellular tPA, which is an important gatekeeper for glutamate-induced
phase shifting. NMDARs are also important mediators of glutamate signals in the SCN,
and LRP-1 can influence NMDAR activity. And finally, TrkB receptors act to gate phase
shifts, and LRP-1-Trk receptor complex formation further strengthens the links between
LRP-1 and known clock regulators. Given these close associations, I hypothesized that
LRP-1 contributes to circadian clock phase regulation. Furthermore, interactions between
LRP-1 and the plasminogen activating cascade, or interactions with NMDARs may
underlie LRP-1s role in the clock. To the best of my knowledge, no studies had assessed
LRP-1 involvement in circadian clock phase shifting prior to my research.
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2 UROKINASE-TYPE PLASMINOGEN ACTIVATOR
MODULATES MAMMALIAN CIRCADIAN CLOCK PHASE
REGULATION IN TISSUE-TYPE PLASMINOGEN ACTIVATOR
KNOCKOUT MICE
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writing. Ashutosh Rastogi, a postdoctoral fellow in the laboratory of Dr. Eric Mintz at Kent
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2.1 Abstract
Glutamate phase shifts the circadian clock in the mammalian suprachiasmatic
nucleus (SCN) by activating NMDA receptors. Tissue-type plasminogen activator (tPA)
gates phase shifts by activating plasmin to generate m(ature) BDNF, which binds TrkB
receptors allowing clock phase shifts. Here, we investigate phase shifting in tPA knockout
(tPA−/−; B6.129S2-Plattm1Mlg/J) mice, and identify urokinase-type plasminogen activator
(uPA) as an additional circadian clock regulator. Behavioral activity rhythms in tPA−/− mice
entrain to a light-dark (LD) cycle and phase shift in response to nocturnal light pulses with
no apparent loss in sensitivity. When the LD cycle is inverted, tPA−/− mice take significantly
longer to entrain than C57BL/6J wild-type (WT) mice. SCN brain slices from tPA−/− mice
exhibit entrained neuronal activity rhythms and phase shift in response to nocturnal
glutamate with no change in dose-dependency. Pre-treating slices with the tPA/uPA
inhibitor, plasminogen activator inhibitor-1 (PAI-1), inhibits glutamate-induced phase
delays in tPA−/− slices. Selective inhibition of uPA with UK122 prevents glutamate-induced
phase resetting in tPA−/− but not WT SCN slices. tPA expression is higher at night than the
day in WT SCN, while uPA expression remains constant in WT and tPA−/− slices. Caseinplasminogen zymography reveals that neither tPA nor uPA total proteolytic activity is
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under circadian control in WT or tPA−/− SCN. Finally, tPA−/− SCN tissue has lower mBDNF
levels than WT tissue, while UK122 does not affect mBDNF levels in either strain.
Together, these results suggest that either tPA or uPA can support photic/glutamatergic
phase shifts of the SCN circadian clock, possibly acting through distinct mechanisms.

2.2 Introduction
In mammals, the suprachiasmatic nucleus (SCN) of the hypothalamus is the
primary circadian pacemaker, maintaining and synchronizing the daily rhythms of diverse
physiological and behavioral processes (Moore & Eichler, 1972; Stephan & Zucker, 1972).
The SCN exhibits self-sustaining oscillations in neuronal activity patterns that synchronize
to the environment primarily through entrainment to light stimuli, a process known as
photic entrainment. Photic entrainment depends on glutamate release onto SCN neurons
inducing shifts in the phase of the underlying clock (Liou et al., 1986; Ding et al., 1994;
Porterfield et al., 2007; Porterfield & Mintz, 2009).
Glutamate binds to NMDA receptors (NMDAR) to initiate a calcium influx and
activate nitric oxide synthase. This stimulates protein kinases and transcriptional
regulators to reset the core clock mechanism by altering the transcription of clockassociated genes (Ding et al., 1997; Gillette & Tischkau, 1999; Butcher et al., 2003; Pizzio
et al., 2003; Butcher et al., 2004; Marpegan et al., 2004; Butcher et al., 2005). Lightinduced phase shifts require concurrent activation of tropomyosin receptor kinase B (TrkB)
via brain-derived neurotrophic factor (BDNF) binding. TrkB gates phase shifts through
mechanisms that remain unclear, allowing them to only occur at night (Liang et al., 1998;
Liang et al., 2000). The proteolytic conversion of proBDNF to m(ature)BDNF, mediated
by plasmin, regulates BDNF signaling (Plow et al., 1995; Lee et al., 2001; Mou et al.,
2009b).
The plasminogen activating system consists of various proteases, their inhibitors,
and their receptors that collectively control the activation of plasminogen into plasmin
(Saksela & Rifkin, 1988; Plow et al., 1995; Cesarman-Maus & Hajjar, 2005; Collen &
Lijnen, 2005). Members of this system, including tissue-type plasminogen activator (tPA),
urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1),
urokinase plasminogen activator receptor (uPAR), neuroserpin, and plasminogen
modulate neuronal processes throughout the brain (Samson & Medcalf, 2006). Of these,
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tPA has received the most attention within the central nervous system (CNS) and its role
as a neuromodulator is well established (Soreq & Miskin, 1981; Sappino et al., 1993;
Fernandez-Monreal et al., 2004; Melchor & Strickland, 2005; Samson & Medcalf, 2006;
Casse et al., 2012a). In the hippocampus, tPA proteolytic activity converts plasminogen
into plasmin, and plasmin can exert downstream effects on synaptic plasticity by
influencing extracellular matrix remodeling or by proteolytically generating mBDNF from
proBDNF (Pang & Lu, 2004; Pang et al., 2004; Melchor & Strickland, 2005). There are
also BDNF-independent and plasminogen-independent synaptic effects of tPA.

For

example, tPA can influence neuronal activity by modulating NMDAR activity and through
interactions with specific receptors including low density lipoprotein receptor-related
protein 1 (LRP-1) and annexin II (Nicole et al., 2001; Fernandez-Monreal et al., 2004;
Zhang et al., 2009b; Baron et al., 2010; Jullienne et al., 2011). tPA’s activity is carefully
controlled by its inhibitor, PAI-1, and the PAI-1 stabilizing protein vitronectin (Schleef et
al., 1991; Delegue et al., 1998; Huntington & Carrell, 2001; Minor & Peterson, 2002;
Mayasundari et al., 2004).
uPA also converts plasminogen into plasmin, is inhibited by PAI-1, is expressed in
the CNS,

and influences a variety of neuronal processes including Schwann cell

migration, nerve regeneration, epilepsy, dendritic spine recovery following stroke, and
amphetamine and morphine-induced reward (Ploug & Kjeldgaard, 1956; Hayden & Seeds,
1996; Iyer et al., 2014; Wu et al., 2014; Karagyaur et al., 2015). However, much remains
unknown about the specific mechanisms of uPA’s involvement in modulating neuronal
responses (Soleman et al., 2013; Chang et al., 2014; Katic et al., 2014; Lino et al., 2014;
Wu et al., 2014). Importantly, little has been done to characterize the interactions between
tPA and uPA in neuronal systems (Bahi & Dreyer, 2008).
The plasminogen activating system regulates circadian phase resetting in the SCN
(Mou et al., 2009b). Using PAI-1 as a tPA inhibitor, our previous study showed that tPA
proteolytic activity gates glutamate-induced phase shifting by generating plasmin, which
cleaves proBDNF into mBDNF, which then binds to the TrkB receptor to allow glutamate
to induce a phase shift (Mou et al., 2009b). Here, we investigate phase shifting in tPA-/mice and shift our attention to possible involvement of uPA in circadian clock regulation.
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2.3 Materials and Methods
2.3.1 Animals
All experiments used C57BL/6J wildtype (WT) mice from Harlan Labs or Jackson
Laboratory, or tPA knockout (B6.129S2-Plattm1Mlg/J; tPA-/-) mice. Male and female tPA-/mice were generated at and purchased from the Jackson Laboratory (Bar Harbor, Maine,
USA). The tPA-/- mice were fully backcrossed for at least 8 generations into the same
background C57BL/6J strain as WT, and the C57BL/6J strain is the recommended control
for the tPA-/- mice. WT and tPA-/- mice were bred and group-housed in the Kent State
University animal facility and the University of Tennessee Knoxville animal facility in a 12hlight/12h-dark cycle (12L:12D) and fed ad libitum. Male (in vivo and in vitro experiments)
and female (in vivo experiments) mice aged 6-12 weeks of age at the beginning of each
experiment were used, and the animals used for each study were age-matched as closely
as possible. Experiments were conducted in accordance with Kent State University
Institutional Animal Care and Use Committee (in vivo work) and the University of
Tennessee Knoxville Institutional Animal Care and Use Committee (in vitro work).

2.3.2 In vivo methods
Entrainment
Six tPA-/- and six WT mice were utilized to examine the rate of entrainment to a
shifted LD cycle. After at least two weeks of baseline activity measurement, the light cycle
was inverted (shifted by 12 hrs). Activity patterns were monitored until all animals showed
stable entrainment to the shifted LD cycle. Entrainment was defined as the date when the
activity onset no longer shifted further on the subsequent day, and when the offset of
activity was no longer showing further progression towards the time of light onset. The
number of days until a stable phase of activity onset was reestablished was measured for
each animal. Differences between genotypes were assessed using a two-sample t-test.
Phase shifting response to light pulses
Animals were individually housed in constant dark for at least 10 days with free
access to running wheels and activity was monitored using Clocklab software. tPA-/- and
WT mice were given a light pulse of either 300, 50, or 5 lux for 15 min at CT16 or 300 lux
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at CT22, determined by activity onset defined as CT12 (n=3-6). Light intensities were
measured at the cage bottom using a lux meter, and each animal was exposed to only
one light pulse. Phase shifts were calculated using ClockLab software. This software
utilizes a linear regression method proposed by Daan and Pittendrigh (Daan & Pittendrigh,
1976). A line was fit to activity onsets 10 days prior to the light pulse. A second line was
fit to activity onsets 4-10 days after light pulse. Days 1-3 after the light pulse were not
included in the data analysis. The phase shift was equal to the difference between the
two regression lines.
Free running periods
Six WT and six tPA-/- mice were housed on a LD cycle, then transferred to DD for
three weeks, LL for three weeks, and DD for three weeks again. Free running period was
assessed in the last 10 days of each condition with Chi-squared periodograms.
2.3.3

In vitro methods

Brain slice preparation
Coronal brain slices (500 μm) containing the SCN were prepared from brains
dissected following rapid decapitation of unanaesthetized adult male (>8 weeks old) WT
or tPA-/- mice, housed in a 12:12 LD cycle. Slices were maintained as previously described
(Prosser et al., 2003; Yamada and Prosser, 2014) in a Hatton-style brain slice dish,
perfused constantly with oxygenated Earle’s Balanced Salt Solution (EBSS; SigmaAldrich) supplemented with glucose, bicarbonate, and gentamicin (pH 7.4) at 37˚ C. One
mouse was used for each experiment and replicate experiments were performed on
different mice.
Slice treatments
Drug treatments were bath applied on the first day in vitro following previously
established protocols (Prosser et al., 2003; Yamada and Prosser, 2014). At ZT16 or ZT23
(Where ZT0 = lights-on in the donor animal colony, and ZT12 = lights-off) perfusion was
stopped and the medium in the slice chamber was replaced with EBSS medium
supplemented with PAI-1 (5 nM; Molecular Innovations Novi, MI, USA), uPA inhibitor (200
nM; UK122 from Santa Cruz, Dallas, TX, USA), and/or glutamate (1 μM – 1 mM; SigmaAldrich). For blocking experiments, slices were pretreated for 30 minutes with inhibitor
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only (PAI-1 or UK122) starting at ZT15.5 (phase delays) or ZT 22.5 (phase advances),
followed by 10 min treatment with 1 mM Glutamate + inhibitor. After 10 minutes the
medium was replaced with normal medium and perfusion was reinstated. Glutamate
alone treatments were applied for 10 minutes. PAI-1 or UK122 alone treatments were
applied for 40 minutes starting at ZT15.5.
Single unit activity (SUA) recordings
Extracellular, single-cell recordings of neuronal activity were made on day 2 in
vitro, using methods previously described (Prosser et al., 1994a; Prosser et al., 1994c;
Ding et al., 1997; Prosser, 1998a; Soscia & Harrington, 2004; Tischkau et al., 2004). A
glass micropipette containing 3M NaCl was lowered into the SCN until the signal from an
individual neuron was isolated. The cell’s activity was recorded for 5 minutes, after which
the electrode was moved to find a new cell. Data acquisition and analysis were done
using the computer program DataWave (DataWave Technologies, Loveland, CO, USA).
Neuronal activity was sampled in this way for 10 hours (h). The firing rates of individual
cells were then grouped into 2 h running means. Time of peak activity was determined as
the time of symmetrically highest activity. The difference in time-of-peak of untreated slices
vs. drug-treated slices was calculated to determine phase shifts. A minimum of 3 biological
replicates were run for each experimental condition.

2.3.4 Western blots
Slices containing the SCN were maintained as described above then collected and
immediately frozen at ZT6, ZT16, and ZT23. To control the amount of time slices were
maintained in vitro, the following slicing and collecting paradigm was used: slices collected
at ZT6 on day 1 in vitro were made at ZT2 (time in vitro = 4 h); slices collected at ZT16 on
day 1 in vitro were made at ZT8 (time in vitro = 8 h); slices collected at ZT23 on day 1 in
vitro were made at ZT3 (time in vitro = 20 h); and slices collected at ZT6 on day 2 in vitro
were made at ZT10 (time in vitro = 20 h). SCN of two mice were pooled for each sample.
For mBDNF experiments, WT and tPA-/- SCN slices were either left untreated or incubated
with 200 nM UK122 for 40 minutes starting at ZT15.5. Slices were stored at -80˚ C until
protein extraction.

Samples were sonicated and incubated in RIPA lysis buffer

supplemented with protease inhibitor cocktail and phosphatase inhibitor. Equal amounts
of protein, determined by Bradford assay, were resolved by SDS-PAGE and transferred
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to PVDF membranes. Membranes were blocked and proteins were detected with primary
antibodies. Membranes were then probed with LI-COR IRDye secondary antibodies,
which were detected using an Odyssey infrared imaging system (IRDye 800CW Donkey
anti-Rabbit (926-32213; 1:10,000) and IRDye 680RD Donkey anti-Goat (925-68074;
1:10,000; LI-COR Biosciences, Lincoln, NE, USA). The following primary antibodies were
used in this study: anti-tPA (ASMTPA-GH; 1:1000) and anti-uPA (ASMUPA-GF-HT;
1:1000) from Molecular Innovations (Novi, MI, USA), anti-BDNF (SC-546; 1:200) and antiactin (SC-1616; 1:2000) from Santa Cruz (Dallas, TX, USA).

Band density was

determined using Image Studio software. Results were normalized to actin as a load
control, and then reported as a ratio to ZT6 (uPA and tPA) or to WT (mBDNF). Positive
controls: purified uPA (MUPA) and tPA (MTPA) from Molecular Innovations (Novi, MI,
USA). A minimum of 4 biological replicates were run for each experimental condition.

2.3.5 Casein-plasminogen gel zymography
Enzyme activities of uPA and tPA in SCN tissue were examined by caseinplasminogen gel zymography, which provides a preliminary measure of proteolytic activity
in the slice. Slices were collected at ZT6, ZT12, ZT16, and ZT23 using the same protocol
as for western blots. SCN from 2 mice were pooled for each sample. Slices collected at
ZT12 on day 1 in vitro were made at ZT6 (time in vitro = 6 h) and slices collected at ZT12
on day 2 in vitro were made at ZT6 (time in vitro = 30 h). Slices were homogenized and
incubated in zymography lysis buffer without protease or phosphatase inhibitors. Equal
amounts of protein (by Bradford assay) were resolved by SDS-PAGE using a 10%
polyacrylamide gel supplemented with 2 mg/mL casein and 4.5 μg/mL human
plasminogen (HGPG; Molecular Innovations). After electrophoresis, gels were incubated
in 2.5% Triton-X 100 for 30 minutes twice, incubated in 100mM Tris buffer, pH8.8 for 3.5
h at 37 ˚C, and stained with Coomassie brilliant blue (Sigma-Aldrich). Purified tPA and
uPA (Molecular Innovations) were used as positive controls, and proteolytic activity was
observed as a clear region of degradation on a dark background. Gels were imaged using
an Odyssey infrared imaging system, and band density was determined using Image
Studio software. In some cases, gels were imaged using a camera system and band
density was determined using ImageJ. Results were reported as a ratio to ZT23. A
minimum of 3 biological replicates were run for each experimental condition.
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2.3.6 Statistical methods
All statistical analysis was performed using SigmaPlot. Individual animals were the
experimental units for the behavioral experiments. Tissue from a single animal (or pooled
when necessary) were the experimental units for the electrophysiology and
immunoblotting experiments. For comparisons of means in samples with normal
distributions and homogeneous variances (as indicated by a Levene’s test), an
independent-sample t test or ANOVA was used for comparisons between two means or
two or more means, respectively. In cases where normality test failed, a Kruskal-Wallis
One Way Analysis of Variance on Ranks was used in place of the ANOVA. Significance
was considered to be P < 0.05.

2.4 Results
2.4.1 tPA−/− mice exhibit normally entrained behavioral activity rhythms, a slight
reduction in the rate of entrainment to new LD, normal phase-shifting
response to light pulses, and normal free-running periods
Entrainment
tPA-/- mice appear to show a normal behavioral pattern when entrained to a LD
cycle, comparable to that observed in WT mice. When the light cycle was inverted, tPA-/mice took significantly longer (5.67 ± 0.33 days) than WT mice (3.83 ± 0.40 days) to
achieve a stable onset of activity at the new time of lights off (t10 = 3.51, P = 0.006). Visual
inspection of actograms suggests that the tPA-/- mice also show increased activity during
the light phase during the transition period to the new dark onset (Figure 2.1).
Light-induced phase shifts
In this experiment, the light-induced phase response of mice deficient in tPA was
evaluated in comparison to wildtype mice. tPA-/- did not exhibit a significantly different
light-induced phase response in comparison to WT when given a light pulse at either ZT16
at 300 (tPA-/- = -2.1 ± 0.39 and WT = -2.5 ± 0.59, t6 = 0.57, P = 0.59; ), 50 (tPA-/- = -1.9 ±
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Figure 2-1. Entrainment in WT vs tPA-/- mice.
Representative actograms for (A) a C57BL/6J mouse (WT) and (B) a tPA−/− mouse after
a 12-h shift in the LD cycle, showing an apparent difference in the time to entrain. Gray
denotes dark period (C) Mean time to entrain to a 12-h shift in the light-dark cycle. P <
0.05. n = 6 for each group.
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0.08 and WT = -1.8 ± 0.27, t9 = 0.21, P = 0.84), or 5 lux (tPA-/- = -1.4 ± 0.19 and WT = 1.2 ± 0.27, t10 = 0.61, P = 0.55) or ZT22 at 300 lux (tPA-/- = 0.4 ± 0.02 and WT = 0.5 ±
0.16, t3 = 0.47, P = 0.67) (Figure 2.2).
Free running periods
The free running period was assessed for 6 WT and 6 tPA-/- mice in DD, then LL,
then a second time in DD. There were no significant differences in free-running period
between genotypes in the first DD period (WT: 23.78 ± 0.07 h; KO: 23.80 ± 0.07 h, t10 =
0.17, P = 0.87), LL (WT: 24.81 ± 0.17; KO: 24.85 ± 0.08, t10 = 0.22, P = 0.83), or the
second DD period (WT: 23.84 ± 0.05; KO: 23.79 ± 0.09, t10 = 0.52, P = 0.61).

2.4.2 SCN slices from tPA−/− mice exhibit entrained neuronal activity rhythms that
phase-shift in response to glutamate
To further investigate circadian entrainment and phase shifting in tPA-/- mice, we
recorded neuronal activity from SCN brain slices of tPA-/- mice in control (untreated)
conditions and following glutamate treatment. In tPA-/- brain slices, SCN neuronal activity
recorded on day 2 in vitro exhibited a circadian rhythm with a peak during mid-day (Fig
3a). The mean (± SEM) time of peak neuronal activity in control tPA-/- brain slices was at
ZT6.1 ± 0.5 (n = 4) (Figure 2.3a).

This time of peak is consistent with that of WT mice

(ZT6), indicating that the circadian clock of tPA-/- mice exhibits normally entrained neuronal
activity rhythms. These results are also consistent with the normal entrainment of
behavioral rhythms seen in vivo. Glutamate (1 mM) applied to SCN slices in the early
subjective night (ZT16) for 10 minutes delayed the time of peak of neuronal activity to
~ZT9 (Fig 3b), with a mean phase-shift of -3.1 ± 0.7 hr (n = 4). Glutamate (1 mM) applied
to the SCN in the late subjective night (ZT23) advanced the time of peak neuronal activity
to ~ZT4 (Figure 2.3c). No significant differences were found between WT and tPA-/- at
either ZT16 or ZT23. These data are summarized in Figure 2.3d. Together, they indicate
that SCN of tPA-/- mice to phase shift in response to glutamate.
To more closely examine potential differences between WT and tPA-/-, we
generated dose response curves for glutamate-induced phase shifts in SCN brain slices
from WT and tPA-/- mice. For these experiments, WT and tPA-/- brain slices were treated
at ZT16 with varying concentrations of glutamate for 10 minutes. Glutamate induced
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Figure 2-2. Light-induced phase shifts in WT vs tPA-/- mice
Mean phase shift of behavioral activity rhythms of WT and tPA−/− mice in response to a
15-min light pulse at CT 16 (first three bars) or CT 22 (rightmost pair of bars). n = 3–6 per
group. X-axis denotes light intensity (lux). No significant differences between pairs at all
intensities.
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Figure 2-3. Glutamate-induced phase shifting in vitro in WT vs tPA-/- SCN.
SCN from tPA−/− mice exhibit entrained neuronal activity rhythms that phase shift in
response to glutamate. Shown here are the 2-h means ± SEM of the spontaneous
neuronal activity recorded in single experiments. (A) Control experiment shows peak
activity at ZT6. (B) Glutamate (1 mm) treatment at ZT16 induces a ~4-h phase delay. (C)
Glutamate (1 mm) at ZT23 induces a ~2-h phase advance. Glutamate-induced phase
shifting tPA−/− SCN is comparable to shifting in WT. (D) Shown are mean ± SEM phase
shifts induced by 1 mm glutamate. Delays are plotted as negative values. In both WT and
tPA−/− mice glutamate at ZT16 induces an approximately 3-h phase delay, while glutamate
at ZT23 induces a phase advances. (E) Varying concentrations of glutamate were applied
to WT or tPA−/− SCN slices at ZT16 to generate dose–response curves. No significant
differences were found when comparing WT to tPA−/−, n = 3–4. ZT, Zeitgeber time.
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similar phase shifts in tPA-/- and WT brain slices at all the concentrations used (Figure
2.3e). No significant differences were found in the magnitude of phase shifts in the WT
and tPA-/- tissue at all concentrations, although there appears to be a trending difference
at intermediate glutamate concentrations: 1 µM (tPA-/- = -0.33 ± 0.17 and WT = 0.33 ±
0.44, t4 = 1.41, P = 0.23), 10 µM (tPA-/- = -1.83 ± 0.73 and WT = -2.42 ± 0.3, t4 = -0.74, P
= 0.5), 100 µM (tPA-/- = -1.00 ± 0.58 and WT = -2.08 ± 0.17, t4 = -1.86, P = 0.14), or 1 mM
(tPA-/- = -3.31 ± 0.47 and WT = -3.08 ± 0.51, t5 = 0.33, P = 0.76). Collectively, these
results indicate that tPA-/- circadian clock phase shifts in response to in vitro glutamate in
a manner that does not differ substantially from WT. Again, these results are consistent
with our in vivo data showing normal photic phase shifting in tPA-/- mice. While on the
surface these data seem at odds with our previous work showing that inhibiting tPA
prevents glutamate induced phase shifting, alternatively they suggest a potential
redundant or compensatory mechanism allowing phase shifting in the circadian clock of
tPA-/- mice (Mou et al., 2009b). Given that PAI-1 also inhibits the enzymatic activity of
uPA, uPA was a logical alternative mechanism acting in the absence of tPA.
2.4.3

tPA and uPA are both expressed in the SCN
We have previously demonstrated that tPA is expressed in the SCN (Mou et al.,

2009b). Here we investigated tPA protein expression in SCN brain slices from WT and
tPA-/- mice across circadian time. Slices were collected at ZT6, ZT16, and ZT23 on the
first day in vitro and at ZT6 on the second day in vitro, then subjected to western blotting.
As shown in Fig 4, in WT SCN we find that tPA expression is higher at night (ZT16 and
ZT23) than during the day (ZT6), and this rhythm persists into the second day in vitro (oneway ANOVA: n = 5, F6 = 5.56, P = 0.008). As expected, no tPA protein was present in
tPA-/- SCN tissue.
Next, we used western blotting to assess uPA expression in the SCN of WT and
-/-

tPA mice across the same time-points used above. Anti-uPA antibody identified an
approximately 55 kDa band in SCN samples from WT and tPA-/- brain slices, supporting
uPA protein expression in SCN. In both WT and tPA-/- SCN uPA expression was constant,
with no significant differences across any groups (one way ANOVA: n = 7, H7 = 3.99, P =
0.78), indicating no circadian rhythm in uPA protein expression (Figure 2.4). In addition,
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Figure 2-4. tPA and uPA expression in SCN of WT and tPA-/- mice.
tPA expression is circadian in vitro, and uPA expression is constant. Proteins extracted
from the SCN were subjected to western blotting. (A) Representative images showing tPA
band at ~70 kDa, and actin load control (~42 kDa). tPA bands are not present in the
tPA−/−. (B) Histogram showing tPA relative to actin, normalized to ZT6 in WT SCN. Oneway ANOVA P = 0.008, n = 5. (C) Representative images showing uPA band at ~55 kDa,
and actin load control (~42 kDa). (D) Histogram showing uPA relative to actin, normalized
to ZT6 in WT and tPA−/− SCN. n = 5–7, no significant differences.
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there appears to be no compensatory changes in uPA protein expression in SCN tissue
from tPA-/- mice.
2.4.4

PAI-1 blocks phase delays in tPA−/− mice
tPA and uPA have overlapping functions as plasminogen activators, and while the

kinetics of uPA release in the synapse are different than those of tPA, examples of
functional redundancy between these proteases have been seen in previous studies
(Carmeliet et al., 1994; Leonardsson et al., 1995; Bugge et al., 1996). Therefore, we
investigated the possibility that uPA can compensate for the lack of tPA to enable phase
shifting in the tPA-/- mice. First, we used PAI-1 to inhibit uPA in SCN brain slices from tPA/-

mice. PAI-1 inhibits both tPA and uPA and blocks phase shifts in WT SCN brain slices

with an ED50 of 0.6 nM, which is comparable to its concentration in serum (Mou et al.,
2009b).

Pretreating SCN slices from tPA-/- mice for 30 minutes prior to glutamate

treatment with 5 nM PAI-1 blocked glutamate-induced phase delays (mean phase-shift =
-0.8 ± 0.4 h, n = 3; Glutamate vs Glutamate + PAI-1: t5 = -3.38, P = 0.02) (Figure 2.5).
When applied alone for 40 minutes, 5 nM PAI-1 had no effect on the phase of the neuronal
activity rhythm. Thus, inhibiting uPA in tPA-/- brain slices prevents glutamate-induced
phase delays in neuronal activity rhythms. Since PAI-1 has no known high-affinity targets
other than tPA and uPA, this supports the hypothesis that uPA may be compensating for
the loss of tPA in the tPA-/- mice.

2.4.5 Selective inhibition of uPA prevents glutamate-induced phase resetting in
the SCN of tPA−/− but not WT mice
To directly address the involvement of uPA in circadian clock phase shifting, we
utilized the uPA specific small molecule inhibitor UK122, which is selective for uPA at low
concentrations (uPA ED50 = 200nM) (Zhu et al., 2007). SCN slices from WT and tPA-/mice were treated with 200 nM UK122 for 30 minutes prior to glutamate application at
ZT16 and ZT23, and then recordings of neuronal activity rhythms were conducted during
the next day. Treating SCN slices from WT mice with 1 mM glutamate + 200 nM UK122
at ZT16 results in a phase delay of 2.8 hr, with a mean time of peak occurring at ZT8.8 ±
0.6 (n = 3, Figure 2.6a). 200 nM UK122 applied alone for 40 minutes at ZT16 had no
effect (Figure 2.6). These results show that in WT SCN tissue, where tPA is present,
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Figure 2-5. PAI-1 inhibits glutamate-induced phase delays in tPA-/- SCN.
5 nm PAI-1 prevents glutamate-induced phase delays in tPA−/− mice. Shown are mean ±
SEM phase-shifts induced by treatments indicated applied to SCN slices of tPA−/− mice.
Phase delays plotted as negative values. *P < 0.05, n = 3.
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Figure 2-6. Selective inhibition of uPA prevents glutamate-induced phase resetting
in the SCN of tPA−/− but not WT mice.
Selective inhibition of uPA prevents glutamate-induced phase shifts in tPA−/− but not WT
mice. Shown are representative trace of SUA recordings from a single SCNs treated with
1 mm glutamate and 200 nm uPA inhibitor (UK122): (A) WT treated at ZT16 shows an
~2.5 h phase delay; (B) tPA−/− treated at ZT16 shows peak activity at ~ZT6.57; (C) Shown
are mean ± SEM phase shift induced by treatments indicated at ZT16. *P = 0.02 n = 3;
(D) WT treated at ZT23 shows an ~3 h phase advance; (E) tPA−/− treated at ZT23 shows
peak activity at ~ZT6.75; and (F) Mean ± SEM phase shift induced by treatments indicated
at ZT23. *P = 0.02, n = 3.
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inhibiting uPA is not sufficient to prevent glutamate-induced phase delays of the SCN
circadian clock (WT: Glutamate vs Glutamate + UK122 at ZT16: t4 = -0.318, P = 0.77).
However, when SCN slices from tPA-/- mice were treated at ZT16 with glutamate + UK122,
the uPA inhibitor prevented glutamate-induced phase delays (mean phase shift = -0.4 ±
0.3 h, n = 3, Figure 2.6b) (tPA-/-: Glutamate vs Glutamate + UK122 at ZT16: t5 = -3.35, P
= 0.02). Again, application of UK122 alone for 40 minutes at ZT16 had no effect on the
phase of SCN neuronal activity rhythm (Figure 2.6). At ZT23, treating WT slices with 1
mM glutamate + 200 nM UK122 resulted in a phase advance of 3.34 ± 0.35 h, while the
same treatment in tPA-/- SCN slices resulted in no phase shift, with a mean time of peak
occurring at ZT6 ± 0.58 h (Figure 2.6f). Thus, inhibiting uPA prevents glutamate-induced
phase advances in tPA-/- SCN but not WT SCN (WT: Glutamate vs Glutamate + UK122 at
ZT23: t4 -1.80, P = 0.15; tPA-/-: Glutamate vs Glutamate + UK122 at ZT23: t4 = 3.51, P =
0.03.) Collectively, this suggests that uPA contributes to circadian clock phase shifting in
tPA-/- mice, further confirming uPA as a mechanism of redundancy within the SCN.

2.4.6 tPA and uPA enzymatic activity in the SCN
In addition to assessing their overall expression, it is important to determine the
proteolytic activity of these proteases. We used casein-plasminogen gel zymography to
assess tPA and uPA proteolytic activity in the SCN. WT and tPA-/- SCN slices were
collected at ZT6, ZT12, ZT16, and ZT23 on the first day in vitro, and at ZT6 and ZT12 on
the second day in vitro. Equal amounts of total protein extracted from the SCN in the
absence of protease inhibitors were subjected to casein-plasminogen gel zymography.
Two regions of degradation were present in WT SCN: one band at ~70 kDa corresponding
with the tPA positive control and one band at ~33 kDA corresponding with the uPA positive
control. These results confirmed the presence of proteolytically active uPA and tPA in the
SCN of WT mice.
We found no significant differences in tPA proteolytic activity in WT SCN across
all time points (one way ANOVA: n = 3 to 15, H5 = 4.63, P = 0.46; Figure 2.7a-c). As
expected, no tPA proteolytic activity was present in the tPA-/- SCN tissue. uPA proteolytic
activity in both WT and tPA-/- SCN increased over the first ~24 h that slices were
maintained in vitro, and then appeared to stabilize at this higher level, but it did not exhibit
a circadian rhythm (one-way ANOVA: n= 3 to 15, H5 = 40.91, P < 0.001; Fig 7d). These
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Figure 2-7. tPA and uPA activity in WT and tPA-/- SCN.
tPA proteolytic activity is not circadian in the mouse SCN in vitro. (A) Representative
casein-plasminogen gel zymograms of protein extracts from SCN of WT and tPA−/− mice
collected at ZT6, ZT16, ZT23 and a second day in vitro ZT6 and (B) an extended time
course of protein extracts from WT SCN collected at ZT12, ZT23, and second day in vitro
ZT6 and ZT12 (all samples are presented in chronological order). tPA (~70 kDa) and uPA
(~30 kDa) proteolytic activity appears as clear bands of degradation on a dark background
that are distinguishable based on molecular weight. (C) Shown is tPA proteolytic activity
in WT SCN normalized to ZT23, no significant differences in One-way ANOVA, n = 3–15.
tPA proteolytic activity is not present in the tPA−/− SCN. (D) Shown is mean ± SEM relative
uPA proteolytic activity in WT SCN normalized to ZT23, One-way ANOVA P < 0.001, n =
3–15. Increase is correlated with increasing time in vitro, not ZT. (E) uPA proteolytic
activity is not significantly different in tPA−/− mice when compared to WT normalized to
ZT6. Shown are means ± SEM relative uPA activity from WT and tPA−/− SCN collected
at the indicated time points. No significant differences when comparing WT and tPA−/− at
each ZT, n = 7.
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results suggest that neither tPA nor uPA total proteolytic activity in the SCN are under
circadian control in vitro.
When comparing tissue from tPA-/- and WT mice there were no significant
differences in uPA activity at any time-point (Figure 2.7e). This indicates that in tPA-/- SCN
tissue uPA’s involvement in glutamate-induced phase shifting does not involve a
compensatory change in proteolytic activity. Rather, the data support the hypothesis that
uPA and tPA exhibit redundancy in function.

2.4.7 2.4.g BDNF protein expression
To assess the involvement of BDNF in our experiments, SCN brain slices from
both WT and tPA-/- mice received no treatment or were treated with 200 nM UK122 at
ZT16 and relative amounts of mBDNF were assessed via western blotting. We found that
mBDNF levels relative to actin were significantly lower in tPA-/- SCN tissue vs. WT SCN
tissue (t14 = 3.38, P = 0.004). Treatment with UK122 did not induce significant changes in
either WT or tPA-/- tissue (Figure 2.8).

2.5 Discussion
Previous research from our lab supports tPA regulation of circadian clock phase
resetting (Mou et al., 2009b). PAI-1 blocks glutamate-induced phase shifts of the SCN
circadian clock in tissue from WT mice but not from mice lacking the PAI-1 stabilizing
protein, vitronectin (Mou et al., 2009b). Adding plasmin or mBDNF, but not plasminogen
or proBDNF, recovers glutamate-induced phase shifting. Furthermore, mBDNF protein
expression levels are higher in the SCN at night than during the daytime (Liang et al.,
1998). Together, these data support a model where tPA levels increase at night, allowing
activation of plasminogen into plasmin to cleave proBDNF into mBDNF. mBDNF activation
of TrkB receptors concurrent with glutamate activation of NMDAR shifts SCN circadian
clock phase (Liang et al., 1998; Liang et al., 2000; Michel et al., 2006; Mou et al., 2009b).
Here, we expanded our investigation of the plasminogen activating system in the
SCN by assessing circadian function in tPA-/- mice. Somewhat surprisingly, these mice
exhibit normal entrainment to 12:12 LD cycles. However, when the light-dark cycle is
shifted by 12 hours we observe a significant increase in the amount of time needed to
entrain to the new cycle. This could indicate a deficiency in the ability of these mice to shift
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Figure 2-8. BDNF protein expression.
mBDNF levels are lower in tPA−/− SCN tissue, but are not affected by UK122 (200 nm).
(A) Shown are representative blots of mBDNF (~17 kDa) and actin load control (~42 kDa)
from WT and tPA−/− SCN which were treated as indicated. (B) Histogram showing mean
± SEM mBDNF relative to actin, normalized to the first WT sample on each blot. A
significant difference was found when comparing untreated WT to tPA−/−. One-way
ANOVA: n = 4–10; P < 0.05.
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their clock, which would be consistent with the trend towards smaller glutamate-induced
phase shifts observed in vitro. An alternative possibility is that the slower reentrainment
is related to a decrease in photic masking as increased locomotor activity may reduce the
phase shifting effects of light. It should be noted that because of the potential for photic
masking, we cannot state for certain when an animal is entrained – we can say that the
animal appears to be entrained based on the behavioral output. However, the rate of
apparent reentrainment seen here in WT mice are not inconsistent with other experiments
using large changes in the LD cycle. Hannibal et al (2008) reported reentrainment to an
8-hour shift in two days, and Sellix et al (2012) showed 4 days to reentrain to a 6 hour
shift. Time to reentrain may depend on the environment in which the animals were raised,
light intensity and/or specturm, and other factors that differ between labs.
Additional experiments demonstrated that the tPA-/- mice exhibit no differences
from WT mice with respect to their phase shifting responses to light pulses presented at
CT16 and CT-22, over a wide range of intensities. Moreover, the tPA-/- mice do not differ
from WT mice in their free running periods in DD or LL. Thus, our initial behavioral
assessments of these mice indicate a deficiency when exposed to a dramatic inversion of
LD cycles, but no overt differences from WT in photic responsiveness to light pulses.
We also find no severe deficiencies in our in vitro assessment of SCN neuronal
activity in tPA-/- brain slices. The circadian rhythms in SCN spontaneous neuronal activity
are not different from WT SCN, indicating the mice entrain to the 12:12 LD cycle. These
rhythms phase shift in response to glutamate, undergoing phase delays in time-of-peak
neuronal activity when glutamate is applied at ZT16 and phase advances when glutamate
is applied at ZT23. Moreover, glutamate-induced phase shifting in tPA-/- brain slices does
not differ significantly from WT brain slices with respect to magnitude of shift or in its dose
dependency. Given PAI-1’s clear inhibition of glutamate-induced phase shifts in vitro,
these results suggest differences between the effects of pharmacological inhibition and
genetic reduction of tPA (Mou et al., 2009b). Since PAI-1 inhibits both tPA and uPA
activity, we shifted our attention to uPA.
uPA is an ideal candidate for functional redundancy/compensation for tPA in the
SCN because it also cleaves plasminogen to form plasmin. Consistent with this
hypothesis, we found that uPA is expressed in the SCN. We assessed potential circadian
rhythms in tPA and uPA expression, and found that tPA protein levels are higher in the
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night than during the day in the SCN. Conversely, there is no apparent circadian rhythm
in uPA protein expression in WT or tPA-/- SCN tissue. Additionally, uPA protein levels are
not different between WT and tPA-/- SCN tissue, suggesting that there is no compensatory
effect on uPA protein expression in the developmental absence of tPA. These findings
support the idea that uPA may play a role in phase shifting, but at the same time the
unique expression patterns of tPA and uPA point to potential differences in their regulatory
and functional mechanisms. Importantly, our assessments of tPA and uPA expression do
not account for potential differences in their release or cell-type specific localization.
Experiments utilizing in cell culture methods and immunohistochemistry will help clarify
potential differences in these parameters.
In assessing uPA function in the SCN, we find that PAI-1 inhibits glutamateinduced phase delays in tPA-/- mice brain slices. Moreover, the uPA-specific inhibitor
UK122 does not prevent glutamate-induced phase delays or advances of neuronal activity
rhythms in SCN from WT mice, but it does inhibit these phase shifts in SCN from tPA-/mice. These results are important for two reasons. First, they strengthen the conclusion
that uPA can support glutamate-induced phase shifts in the absence of tPA. Second, they
indicate a dynamic interplay between tPA and uPA, suggesting a system where neither
protease is necessary, but each sufficient to enable phase shifting. Importantly, it appears
that at least one plasminogen activator is required for phase shifting to occur. Experiments
in uPA knockout mice will be important to further investigate the roles of these proteases
in circadian clock phase shifting.
We also investigated tPA and uPA enzymatic activity in the SCN. tPA proteolytic
activity does not exhibit a circadian rhythm despite finding higher protein levels at night.
uPA proteolytic activity also does not show a circadian rhythm in the SCN. However, uPA
proteolytic activity increases in parallel with the duration of time the brain slices are
maintained in vitro, despite finding constant protein levels. uPA is secreted as a 55 kDa
high molecular weight (HMW) pro-enzyme that is cleaved into a 2-chain HMW enzyme
that is most active when bound to the uPA receptor (Husain, 1991; Ronne et al., 1991).
The 2-chain HMW uPA can be further cleaved into 2 individual chains: a ~33 kDa active
low molecular weight (LMW) uPA and a ~22 kDa non-active amino terminal fragment
(Lijnen et al., 1987a; Novokhatny et al., 1992).

Because of the different extraction

procedures, our western blotting results assessed the uncleaved ~55 kDa HMW uPA,
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while our zymography results address the ~33 kDa active LMW uPA. Thus, our data could
support distinct regulation of the two forms of uPA in the SCN, a possibility that requires
further exploration. There are reports of uPA involvement in neuronal repair processes,
so it is possible that the increased uPA proteolytic activity we observe across time in vitro
is in response to the tissue injury (Lahtinen et al., 2006; Lahtinen et al., 2010; Lukasiuk et
al., 2011; Cho et al., 2012; Karagyaur et al., 2015). Collectively, these results suggest
that uPA and tPA proteolytic activity are regulated by distinct mechanisms in the SCN. It
is also noteworthy that these proteins are regulated through multiple protein interactions
in the intact system, and these interactions would be disrupted during the tissue extraction
procedures used here (Collen & Lijnen, 2005; Melchor & Strickland, 2005). Therefore, it
is possible that the activity patterns we see in vitro differ from in vivo. Studies utilizing in
situ zymography and cell culture procedures will enhance characterization of the
proteases in the SCN.
Previous studies investigating tPA and uPA redundancy indicate that uPA can
compensate for the absence of tPA through a mechanism that is not related to increases
in protein expression (Siconolfi & Seeds, 2001; Bukhari et al., 2011). Studies assessing
tPA and uPA as mediators of psychostimulant-induced synaptic plasticity and remodeling
demonstrated divergent roles for these plasminogen activators (Bahi & Dreyer, 2008; Al
Maamari et al., 2014). In the SCN, we find no statistically significant differences in either
uPA expression or uPA proteolytic activity between WT and tPA-/- tissue. While noting the
same caveats with respect to in situ regulation, these results suggest that uPA’s
involvement in SCN clock phase shifting in tPA-/- mice is not related to compensatory
differences in either the expression or activity of uPA. However, to verify that there is no
cross-compensation between these two proteases, it will be important to assess tPA
expression and activity in the SCN of uPA-/- mice.
Both tPA and uPA generate plasmin, which can cleave proBDNF into mBDNF.
BDNF regulates NMDA currents in the SCN (Kim et al., 2006; Michel et al., 2006), and
therefore mBDNF generation downstream of the plasminogen activators may contribute
to SCN clock phase shifting. Distinctions between the two proteases in the degree to
which they regulate mBDNF production are unclear: there are numerous studies linking
tPA directly to BDNF maturation, but many fewer demonstrating uPA involvement (Pang
& Lu, 2004; Pang et al., 2004; Gray & Ellis, 2008; Cunha et al., 2010; Rodier et al., 2014).
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Our results add to this literature by demonstrating, first, that mBDNF levels are decreased
by about 50% in tPA-/- SCN tissue relative to WT levels. This is consistent with the effects
seen in other brain regions (e.g., Pang et al., 2004). This suggests that tPA participates in
regulating BDNF maturation in the SCN, but that other proteases are able to function in
this manner as well. Secondly, the data suggest that uPA does not contribute to BDNF
cleavage in the SCN. Thus, the mechanism(s) through which uPA modulates glutamateinduced phase resetting in the SCN appear to be distinct from those through which tPA
acts.
As an additional layer of complexity, BDNF stimulates tPA expression (Fiumelli et
al 1999), enhances uPA release from microglia (Nakajima 1998, 2005), and increases
uPA production (Sun et al 2006). Whether BDNF modulates tPA and/or uPA expression
in the SCN is an interesting question that remains to be determined.
Although our data show similarities between the actions of tPA and uPA, this does
not abrogate them each having actions in the SCN not shared by the other, a conclusion
supported by our mBDNF data; while their proteolytic activities overlap, the two proteins
also display considerable differences. tPA’s interactions with several membrane-bound
receptors, including NMDAR, annexin II, LRP-1, and epidermal growth factor receptor
(EGFR), can influence neuronal responses (Melchor & Strickland, 2005). Conversely, uPA
binding to uPA receptor (uPAR) regulates uPA dependent proteolysis, cell adhesion, and
signaling (Smith and Marshall 2010). Therefore, tPA’s various receptor interactions and
uPA’s uPAR-dependent processes represent unexplored avenues that could influence
SCN circadian clock phase regulation. Additionally, shared functions of tPA and uPA in
the SCN could include processes down-stream of plasmin activation that don’t involve
BDNF.

Plasmin cleaves the extracellular matrix (ECM) to allow cell structure

reorganization, which could be relevant to clock function as several studies have
demonstrated circadian rhythms in micro-cellular rearrangements in the SCN (Soleman et
al., 2013). Plasmin regulation of matrix metalloproteinase (MMP) activity could also
influence circadian clock function (Kaur et al., 2004). MMP’s could provide an additional
mechanism for ECM rearrangement, may be able to feed back into mBDNF generation,
and can influence neuronal responses via modulation of NMDAR activity.
Taken together, these data support a more complex scenario of proteolytic
involvement in SCN circadian clock phase regulation than originally described. In addition
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to tPA activating plasmin to generate mBDNF, we now have evidence that uPA can
support glutamate induced phase resetting, and that uPA acts through distinct
mechanism(s). Given the paucity of information on uPA’s actions in regulating synaptic
plasticity together with the known differences in their signaling mechanisms, these results
create a wonderful opportunity to explore the shared vs. distinct actions of these proteases
in a well-defined model system of synaptic plasticity – the SCN circadian clock. Moreover,
further clarifying how these plasminogen activators function in the SCN to modulate photic
signaling will expand our understanding of circadian clock phase regulation.
In conclusion, our data reinforce the concept that extracellular proteases are
involved in SCN circadian clock phase regulation. By demonstrating a critical role for uPA
and tPA, these results add substantially to those from our previous study with respect to
our knowledge of plasminogen activators modulating plasticity within the SCN. The
possibility that these two proteases may serve functionally redundant roles in the SCN,
and that neither is itself necessary for normal circadian function, would not be
unprecedented. Regarding the SCN circadian clock, functional redundancy appears to be
the norm and these data reinforce this concept (Hastings 2014). Our in vivo studies on
tPA-/- mice tell a similar story, with the genetic deletion of tPA causing minimal disruption
in behavioral entrainment or light-induced phase shifting, although these mice take longer
to entrain to a 12 h shift in the LD cycle. A full understanding of plasminogen activator
functions in SCN clock regulation, including potential interactions with uPAR and/or LRP1 receptors, and extracellular matrix proteins is clearly warranted. Continued exploration
of extracellular protease activities in the SCN should provide greater insight into the
cellular processes modulating circadian clock functioning.
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3 LOW DENSITY LIPPOPROTEIN RECEPTOR-RELATED
PROTEIN-1 REGULATES GLUTAMATE-INDUCED PHASE
SHIFTING IN THE MOUSE SUPRACHIASMATIC NUCLEUS
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3.1 Abstract
Glutamate induces phase shifts of the mammalian suprachiasmatic nucleus (SCN)
circadian pacemaker by activating NMDA receptors (NMDARs). These phase shifts are
restricted to the subjective night by rhythmic activities of m(ature) brain derived
neurotrophic factor (BDNF), TrkB receptors, NMDARs and the plasminogen activators
(PAs), t(issue-type)PA and u(rokinase)PA. These phase shift gating proteins are all
known to interact with low-density lipoprotein receptor-related protein 1 (LRP-1), and here
we investigate whether LRP-1 is also a regulator of SCN clock function. We investigated
LRP-1 expression in the SCN via western blotting, and find that LRP-1 is expressed in the
SCN and that it exhibits both diurnal and time-in-dish dependent variations in expression
patterns. Using electrophysiological recordings of SCN neuronal activity rhythms, we find
that inhibiting LRP-1 with receptor associated protein (RAP) or an LRP-1 specific antibody
in SCN brain slices prepared from wild-type (WT; C57BL/6) mice prevents glutamateinduced phase delays and advances in neuronal activity rhythms at ZT16 and ZT23,
respectively. RAP also prevents glutamate-induced phase delays in tPA knockout mouse
(tPA−/−; B6.129S2-Plattm1Mlg/J) SCN slices. Treating WT SCN slices with combinations
of glutamate and RAP does not alter BDNF maturation or TrkB receptor phosphorylation
on Y680/681.

Treating SCN brain slices with RAP reduces NMDAR NR2B subunit

phosphorylation on S1480, but does not change phosphorylation on Y1472. Collectively,
these results indicate that LRP-1 participates in SCN circadian clock phase regulation,
and that it acts through mechanism(s) that do not require plasminogen activator activity,
but may involve changes in NMDAR localization.

3.2 Introduction
In mammals, the suprachiasmatic nucleus (SCN) of the hypothalamus serves as
the primary circadian pacemaker (Moore & Eichler, 1972; Stephan & Zucker, 1972). It
orchestrates daily rhythms in behavior in physiology by generating endogenous 24 h
cycles, synchronizing them to the environment, and distributing the timing cues to the
body. The primary synchronizing signal in the environment is light, which modulates SCN
clock phase through a process known as photic entrainment. Photic entrainment relies
on light stimulating melanopsin-expressing retinal ganglion cells to release glutamate onto
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SCN neurons (Liou et al., 1986; Ding et al., 1994; Porterfield et al., 2007; Porterfield &
Mintz, 2009). Glutamate binds to and activates NMDA receptors (NMDAR), inducing a
calcium influx that stimulates downstream signaling events, ultimately leading to shifts in
the timing of the circadian clock (Ding et al., 1997; Gillette & Tischkau, 1999; Butcher et
al., 2003; Pizzio et al., 2003; Butcher et al., 2004; Marpegan et al., 2004; Butcher et al.,
2005). The downstream signaling events mediating these phase shifts involve activation
of CaMKII by autophosphorylation of Thr286/287 (Golombek & Ralph, 1995; Fukushima
et al., 1997; Yokota et al., 2001), which in turn activates neuronal nitric oxide synthase
(nNOS) to produce nitric oxide (NO) (Ding et al., 1994; Ding et al., 1997; Melo et al., 1997;
Agostino et al., 2004). Through distinct intracellular pathways (Weber et al., 1995; Ding et
al., 1998; Prosser, 1998b; Tischkau et al., 2003), these initial signaling events lead to
changes in the transcription of core clock genes that can alter the phase of the clock (Ginty
et al., 1993; Ding et al., 1997; Gau et al., 2002) in a time-dependent manner: glutamate
induces phase delays in the early night, phase advances in the late night, and has no
effect on clock phase in the daytime.

The mechanisms regulating the differential

responsiveness have not been fully elucidated (Iyer et al., 2014).
LRP-1 is a large membrane bound endocytic and signaling receptor that modulates
neuronal activity throughout the central nervous system (CNS) (Lillis et al., 2008), and
whose function overlaps with processes known to gate phase shifting of the SCN circadian
clock. LRP-1 is a member of the low-density lipoprotein (LDL) receptor family that binds
over 50 different ligands extracellularly, and upon ligand binding it mediates rapid
endocytosis and/or activation of signal transduction cascades (Lillis et al., 2008). LRP-1
is composed of a 515 kDa extracellular α subunit that is non-covalently associated with
an 85 kDa transmembrane β subunit (Kerrisk et al., 2014; Ramanathan et al., 2015). The
αLRP-1 subunit contains cysteine-rich complement-type ligand binding repeats, and EGF
repeats and β-propeller domains that function in the release of ligands (Lillis et al., 2005).
The βLRP-1 subunit contains a single transmembrane domain and cytoplasmic domain,
which has two NPxY motifs that can be phosphorylated to contribute to endocytosis and
signal transduction (Lillis et al., 2005). LRP-1 is widely expressed throughout the CNS,
and while deletion of the LRP-1 gene is embryonically lethal, neuronal specific deletion of
LRP-1 in mice results in severe behavioral and motor abnormalities, including
hyperactivity, tremor, and dystonia (May et al., 2004; Liu et al., 2010). LRP-1 can be
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expressed in the post-synapse, where it regulates synaptic structural and functional
integrity, partly through regulating glutamate receptors (May et al., 2004; Liu et al., 2010).
One prominent group of LRP-1 ligands, the plasminogen activators (tissue type
plasminogen activator; tPA and urokinase type plasminogen activator; uPA), act to gate
glutamate-induced phase shifts in the SCN (Mou et al., 2009b; Cooper et al., 2017;
Cooper, Submitted). tPA is a secreted serine protease that is widely expressed in the brain
and has well-characterized roles as a neuromodulator (Melchor & Strickland, 2005;
Benarroch, 2007; Medcalf, 2017). uPA is also expressed in the CNS, and while less is
known about its neuromodulatory roles, evidence supports its involvement in neuronal
repair processes (Merino et al., 2017b). tPA expression is rhythmic in the SCN, with higher
levels at night, and inhibiting tPA and uPA with plasminogen activator inhibitor-1 (PAI-1)
prevents in vitro glutamate-induced phase shifts of the mouse SCN circadian clock (Mou
et al., 2009b; Cooper et al., 2017). tPA facilitates glutamate-induced phase shifts by acting
upstream of BDNF, another well-established regulator of glutamate-induced phase shifts
(Liang et al., 2000; Pang & Lu, 2004; Pang et al., 2004; Michel et al., 2006; Mou et al.,
2009b). tPA cleaves plasminogen into plasmin, which cleaves proBDNF into mBDNF
(Pang et al., 2004; Mou et al., 2009b). BDNF levels are also rhythmic in the SCN, such
that high night levels of mBDNF bind to TrkB receptors to enable glutamate-induced phase
shifts (Allen et al., 2005; Mou et al., 2009b). Surprisingly, tPA knockout mice exhibit no
severe deficits in phase-shifting in vivo and in vitro, and uPA appears to compensate,
allowing phase shifting in tPA deficient animals (Cooper et al., 2017). However, inhibiting
uPA does not influence BDDF maturation in SCN slices, suggesting that this functional
compensation may be achieved through BDNF-independent mechanisms (Cooper et al.,
2017).
The plasminogen activators also have non-proteolytic functions in the brain, and
one major interaction mediating tPA effects is LRP-1 binding. Upon binding, tPA can
activate LRP-1 dependent signaling events (Yepes et al., 2003; Zhang et al., 2009b;
Mantuano et al., 2013) and LRP-1 endocytic activity can modify tPA proteolytic activity
(Casse et al., 2012b). In rat Schwann cell primary cultures, LRP-1 induces c-Jun
phosphorylation downstream of tPA binding, which ultimately allows it to function as an
injury detection receptor (Flutsch et al., 2016). tPA binding to LRP-1 activates ERK and
AKT pathways to promote neurite outgrowth, and tPA induces ERK activation through an
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LRP-1 dependent pathway to mediate axonal outgrowth (Fuentealba et al., 2009; Shi et
al., 2009; Qian et al., 2016). tPA enhances long term potentiation (LTP) in hippocampal
slices by binding LRP-1 and activating cAMP/PKA pathways (Zhuo et al., 2000). In other
cases, tPA-dependent effects may involve interactions with other receptors that depend
on LRP-1 activity. For example, tPA potentiates NMDAR calcium influx in an LRP-1
dependent manner (Samson et al., 2008). LRP-1 is also required for tPA-mediated
microglial activation in the CNS following middle cerebral artery occlusion (MCAO) (Zhang
et al., 2009a; Zhang et al., 2009b). In addition to these signaling responses, LRP-1
contributes to tPA recycling in the nervous system. Glutamate induces tPA recycling by
astrocytes via LRP-1 dependent endocytosis and subsequent release of tPA (Casse et
al., 2012b). LRP-1 may also act as a co-receptor increasing tPA activity (Su et al., 2017).
Thus, there is a complex association between tPA and LRP-1 mediated functions in the
nervous system.
A second link between LRP-1 and processes gating circadian clock phase shifting
involves LRP-1 interactions with NMDA receptors. NMDARs are the primary receptors
responsible for photic/glutamate phase shift responses, and there is evidence suggesting
rhythms in the NR2B subunit mRNA and protein expression and phosphorylation patterns
(Bendova et al., 2012). LRP-1 interacts with NMDAR via PSD95 (May et al., 2004).
Inhibiting LRP-1 can decrease NMDAR calcium influx (Bacskai et al., 2000), in part
through LRP-1 modulation of NMDAR trafficking and degradation, thus controlling
NMDAR surface localization (Maier et al., 2013). This pathway is further influenced by
interactions with Trk receptors: LRP-1, NMDAR, and Trk receptors act in complex to
mediate tPA dependent calcium influxes through the NMDAR (Martin et al., 2008), and
LRP-1 mediates transactivation of Trk receptors by a Src family kinase (SFK) dependent
pathway (Shi et al., 2009). LRP-1 may also indirectly influence NMDAR-dependent
signaling by regulating the activity of tPA.
Finally, LRP-1 signaling mechanisms also intersect with intracellular signaling
events associated with glutamate-induced phase shifts.

CaMKII binds LRP-1’s

intracellular domain on Y4506, found on an intracellular NPxY motif that is associated with
LRP-1

endocytosis

and

signaling

events,

preferentially

associating

with

the

unphosphorylated form of LRP-1 (Guttman et al., 2009). NMDAR activation of pCREB in
primary cortical neuron cell cultures is reduced in LRP-1 deficient neurons (Nakajima et
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al., 2013). Finally, as mentioned earlier, LRP-1 rapidly upregulates and activates ERK1/2
(Campana et al., 2006; Mantuano et al., 2008).
Since LRP-1 influences several key players in the SCN circadian clock phase
shifting pathway, including the tPA proteolytic cascade, Trk receptor signaling, and
NMDAR signals, we hypothesized that LRP-1 contributes to glutamate-induced phase
shifting in the mouse SCN in vitro. To address this, we assessed LRP-1 expression in the
SCN, whether it affects in vitro glutamate-induced phase shifts, and potential cellular
mechanisms through which it may act in the SCN, with a specific focus on interactions
with tPA or NMDARs. Our results demonstrate for the first time that LRP-1 is expressed
in the SCN and that it modulates glutamate-induced phase resetting.

3.3 Materials and Methods
3.3.1 Animals
All experiments used C57BL/6 wildtype (WT) male mice from Envigo (Indianapolis,
IN), or tPA knockout (B6.129S2-Plattm1Mlg/J; tPA-/-) male mice. Male and female tPA-/mice were generated at and purchased from the Jackson Laboratory (Bar Harbor, Maine,
USA). The tPA-/- mice were fully backcrossed for at least 8 generations into the same
background C57BL/6 strain as WT, and the C57BL/6 strain is the recommended control
for the tPA-/- mice. tPA-/- mice were bred and group-housed in the University of Tennessee
Knoxville animal facility in a 12 h-light/12 h-dark cycle (12L:12D) and fed ad libitum. Male
mice 6-12 weeks of age at the beginning of each experiment were used, and animals used
for each study were age-matched as closely as possible. Experiments were conducted in
accordance with the University of Tennessee Knoxville Institutional Animal Care And Use
Committee.

3.3.2 Brain slice preparation
Coronal brain slices (500 μm) containing the SCN were prepared from brains
dissected following rapid decapitation of unanaesthetized WT or tPA-/- mice. Slices were
maintained in a Hatton-style brain slice dish, perfused constantly with oxygenated Earle’s
Balanced Salt Solution (EBSS; Sigma-Aldrich, St. Louis, MO, USA) supplemented with
glucose, bicarbonate, and gentamicin (pH 7.4) at 37oC, as previously described (Prosser,
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2003; Yamada & Prosser, 2014). One mouse was used for each experiment and replicate
experiments were performed on different mice.

3.3.3 Slice treatments
Drug treatments were bath applied on the first day in vitro following previously
established protocols (Prosser, 2003; Yamada & Prosser, 2014). At zeitgeber time (ZT)16
or ZT23 (ZT0 = lights on in the donor animal colony, and ZT12 = lights off) perfusion was
stopped and the medium in the slice chamber was replaced with EBSS supplemented with
RAP (50-500 nM, Molecular Innovations Novi, MI, USA), rabbit polyclonal anti-LRP-1
antibody (75 μg/mL, R2629, a generous gift from Dudley Strickland, University of
Maryland), and/or glutamate (1 mM; Sigma-Aldrich). For RAP experiments, slices were
pretreated with for 5 minutes with RAP only, followed by 10-minute treatment with 1 mM
glutamate + RAP, and then 5 minutes post-treatment with RAP only.

For R2629

experiments, slices were pretreated with R2629 only for 20 minutes, then treated for 10
minutes with 1 mM glutamate + R2629. In both cases, after the final incubation the medium
was replaced with normal EBSS and perfusion was reinstated. Glutamate alone
treatments were applied for 10 minutes starting at ZT16 or ZT23. RAP or R2629 only
treatments were applied for 20 or 30 minutes, respectively, with a start time corresponding
to that of the inhibitor + glutamate experiments.

3.3.4 Single unit activity (SUA) recordings
On the second day in vitro extracellular single unit recordings of neuronal activity
were made using methods previously described (Prosser et al., 1994a; Prosser et al.,
1994b; Ding et al., 1997; Prosser, 1998a; Soscia & Harrington, 2004; Tischkau et al.,
2004).

The electrical signal from an individual neuron was isolated using a glass

micropipette containing 3M NaCl, and the cell’s activity was recorded for 5 minutes. The
electrode was then moved to record the electrical signal from a new cell. Sampling started
in the subjective morning (~ZT3) and neuronal activity was sampled for about 10 hr. The
firing rates of individual cells were grouped into 2 h running averages, and the time of peak
neuronal activity was determined as the time of symmetrically highest activity. Each phase
shift was determined by calculating the difference between time-of-peak in untreated
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slices vs drug-treated slices. Three to six biological replicates were performed for each
experimental condition.
3.3.5

Western blots
Brain slices (reduced in size from those for electrophysiology experiments)

containing the SCN and the underlying optic chiasm were prepared and maintained as
described above. Slices (treated or untreated) were collected at various times and
immediately frozen for western blotting experiments.

For time-course experiments,

untreated slices were collected at ZT6, ZT16, and ZT23. To control the amount of time
slices were maintained in vitro, the following slicing and collecting paradigm was used:
slices collected at ZT6 on day 1 in vitro were prepared at ZT2 (time in vitro = 4 h); slices
collected at ZT16 on day 1 in vitro were prepared at ZT8 (time in vitro = 8 h); slices
collected at ZT23 on day 1 in vitro were prepared at ZT3 (time in vitro = 20 h); and slices
collected at ZT6 on day 2 in vitro were prepared at ZT10 (time in vitro = 20 h). Bath
application drug treatments for western blotting were performed as follows: a) 1 mM
glutamate applied for 10 minutes starting at ZT16, then allowed to recover for 5 minutes
in normal media before collecting; b) 1 mM glutamate + 100 nM RAP: Slices were treated
for 5 minutes with 100 nM RAP, then for 10 minutes with 1 mM glutamate + 100 nM RAP,
then 5 minutes 100 nM RAP; c) 100 nM RAP: Slices were treated for 20 minutes with 100
nM RAP then immediately collected; d) untreated controls were collected at ZT16.
Slices were sonicated and incubated in RIPA lysis buffer supplemented with
protease inhibitor cocktail (Thermo Scientific, Waltham, MA) and phosphatase inhibitor
(Thermo Scientific). Equal amounts of protein, determined by Bradford assay, were
resolved by SDS-PAGE (LRP-1 resolved on 3-8% Tris-Acetate gel in non-reducing
conditions; non-covalently connected 515 kDa αLRP-1 and 85 kDa βLRP-1 subunits
dissociate) and transferred to polyvinylidene fluoride (PVDF) FL immobilon membrane
(EMD Millipore, Billerica, MA) using the Transblot turbo system (Bio-Rad Laboratories,
Hercules, CA).

Membranes were blocked and proteins were detected with primary

antibodies. Membranes were then probed with LI-COR IRDye secondary antibodies,
which were detected using an Odyssey infrared imaging system (IRDye 800CW Donkey
anti-Rabbit (926-32213; 1:10 000) and IRDye 680RD Donkey anti-Goat (925-68074; 1:10
000; LI-COR Biosciences, Lincoln, NE, USA). The following primary antibodies were used
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in this study: anti-actin (SC-1616; 1:2000), anti-phospho-Trk Y680/681 (sc-7996-R,
1:1000, pTrk), anti-phospho-LRP-1 Y4507 (sc-33049, 1:1000, pLRP-1), and anti-BDNF
(sc-546, 1:200) from Santa Cruz (Dallas, TX, USA); anti-LRP-1 [5A6] (ab28320, 1:1000,
recognizes βLRP-1), anti-CaMKII (ab22609; 1:1000), and anti-phospho-NMDAR2B
S1480 (ab73014; 1:1000) from Abcam (Cambridge, MA, USA); anti-phospho-NR2B
Y1472 (AB5403; 1:1000) from EMD Millipore (Darmstadt, Germany); anti-phosphoCaMKII Thr286 (p1006-286, 1:1000) from PhosphoSolutions (Auroro, CO, USA) and antiLRP-1 (R2629; 1:1000, recognizes αLRP-1) a gift from Dudley Strickland (University of
Maryland, MD, USA).

Band density was determined using Image Studio software.

Results were normalized to actin as a load control, then reported as a ratio to ZT6 (timecourses) or to no treated control (treatment experiments). The SCN of a single mouse was
used for each sample, and replicate experiments were performed on different mice. Three
to nine biological replicates were run for each experimental condition.

3.3.6 Statistical methods
All statistical analyses were performed using GraphPad Prism. Tissue from a
single animal was the experimental unit for the electrophysiology and immunoblotting
experiments.

For comparisons of means in samples with normal distributions and

homogenous variances (as indicated by a Levene’s test), an independent-sample t test or
ANOVA was used for comparisons between two means or more than two means,
respectively. Significance was considered to be p < 0.05.

3.4 Results
3.4.1 LRP-1 expression and phosphorylation in the SCN
LRP-1 is widely expressed throughout the brain, and here we investigated LRP-1
expression in the mouse SCN in vitro across circadian time. SCN-containing brain slices
were collected at ZT6, ZT16, and ZT23 on the first day in vitro and at ZT6 on the second
day in vitro, and subjected to western blotting analysis. Anti-LRP-1 antibody (R2629)
identified an approximately 515 kDa band, consistent with the αLRP-1 heavy subunit, and
the 5A6 anti-LRP-1 antibody detected an approximately 85 kDa band, consistent with
previous reports of the βLRP-1 light subunit. Identification of both protein subunits in the
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tissue samples supports functional LRP-1 expression in SCN. The relative intensity of the
αLRP-1 515 kDa band was higher at ZT16 and ZT23 than at ZT6 (one-way ANOVA: n =
5-6, F(3,16) = 5.697, p = 0.0226), indicating a diurnal variation in LRP-1 expression (Figure
3.1a). Interestingly, the 85kDa βLRP-1 did not exhibit the same pattern: instead, its
expression decreased in correlation with the time slices were maintained in vitro (one-way
ANOVA: n = 5, F(3,16) = 0.9386, P = 0.0002) (Figure 3.1b). We also assessed LRP-1
phosphorylation on the β subunit using a phospho-specific LRP-1 antibody recognizing
pY4507. In vitro LRP-1 phosphorylation at Y4507 did not exhibit a circadian rhythm, and
also decreased across time in vitro, corresponding with the changes observed for the LRP1 85kDa subunit (one-way ANOVA: n = 3, F(3,8) = 0.5285, P = 0.0026) (Figure 3.1c).
Collectively, these results suggest that LRP-1 expression exhibits both diurnal changes
and time-in vitro dependent changes in vitro, and that the heavy subunit and light subunit
have differing expression patterns.

3.4.2 Inhibiting LRP-1 prevents glutamate induced phase shifts in vitro
To investigate the role of LRP-1 in circadian clock phase shifting, we assessed the
effect of inhibiting LRP-1 on glutamate-induced phase shifts of neuronal activity recorded
in mouse SCN slices. First, we treated SCN slices with 1 mM glutamate +/- RAP, then
conducted extracellular recordings of neuronal activity on the second day in vitro to
determine the time of peak firing rate, which reflects the phase of the underlying circadian
clock. RAP is a potent inhibitor of the LDL receptor family that is commonly used to assess
LRP-1 function (Prasad et al 2015). Consistent with previous reports, 1 mM glutamate
applied for 10 minutes at ZT16 induced a phase delay in SCN peak neuronal activity, with
a mean phase shift of -3.08 +/- 0.51 h; n = 3 (Figure 3.2a). Applying 500 nM RAP
concurrently with glutamate prevented these glutamate-induced phase delays, with a
mean phase shift of -0.56 +/- 0.26 h, n = 4 (t-test glutamate vs glutamate + RAP: n = 3 to
4, t3 = 4.826, p = 0.0048) (Figure 3.2b). Additionally, RAP inhibition of glutamate-induced
phase delays was dose dependent, and 100 nM was sufficient to prevent phase delays
(one-way ANOVA: n = 3 to 4, F(3,9) = 0.1851, p = 0.0027) (Figure 3.2g). 500 nM RAP
applied alone for 20 minutes at ZT16 had no effect on mean time of peak neuronal activity
(one sample t-test of 500 nM RAP vs 0: n = 3, t(2)=1.155, p = 0.3675).

55

Figure 3-1. LRP-1 expression and phosphorylation in SCN in vitro.
LRP-1 is expressed in mouse SCN in vitro, and the α and β subunits are expressed
differentially. Proteins extracted from the SCN were subjected to western blotting
analysis. (A) Representative images showing αLRP-1 band at ~515 kDa, and actin load
control (~42 kDa), and corresponding histogram showing αLRP-1 relative to actin,
normalized to ZT6 in WT SCN. One-way ANOVA p = 0.0485, n = 6. (B) Representative
images and corresponding histogram showing βLRP-1 (~85 kDa) and actin. One-way
ANOVA p = 0.0002, n = 5. (C) Representative images and corresponding histogram for
pLRP-1 Y4507 (~85 kDa) and actin. One-way ANOVA p = 0.0026, n = 3-6.
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Figure 3-2. Inhibiting LRP-1 prevents glutamate-induced phase shifts at ZT16 and
ZT23.
Inhibiting LRP-1 prevents glutamate-induced phase shifts at ZT16 and ZT23. Shown here
are the 2-hr means +/- SEM of the spontaneous neuronal activity recorded in single
experiments, double bar denotes time of treatment, dashed bar indicates time of peak in
neuronal activity rhythm in non-treated control. (A) Glutamate (1 mM) treatment at ZT16
induced a -3.08 +/- 0.51 h phase delay. (B) 100 nM RAP prevented glutamate-induced
phase delays. (C) Shown are mean +/- SEM phase shift induced by treatments at ZT16.
* p < 0.05 (D) Glutamate (1 mM) treatment at ZT23 induced a +2.66 +/- 0.21 h phase
advance. (E) 500 nM RAP prevented glutamate-induced phase advances. (F) Shown are
mean +/- SEM phase shift induced by treatments at ZT23. * p < 0.05 (G) ZT16 RAP dose
response curve. (H) ZT23 RAP dose response curve..
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Figure 3-2 continued
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Because RAP can inhibit multiple members of the LDL receptor family, we
addressed LRP-1 specifically by repeating the experiment using the anti-LRP-1 antibody
R2629 antibody, which selectively inhibits LRP-1 (Mikhailenko et al., 2001). Concurrent
application of 75 μg/mL R2629 with 1 mM glutamate resulted in a mean phase shift of 0.17
+/- 0.17 h, n = 3, indicating that selective inhibition of LRP-1 prevented glutamate-induced
phase delays (t-test comparing glutamate vs glutamate + R2629: n = 3, t(4)=6.091, p =
0.0037) (Figure 3.2c). Again, 75 μg/mL R2629 applied alone for 40 minutes at ZT16 had
no effect on the mean time-of-peak neuronal activity (one sample t-test compared to 0: n
= 3, t(2)=0.4804, p = 0.6784) (Figure 3.2c).
We repeated this series of treatments at ZT23 to address whether LRP-1 also
influences phase advances. As previously reported, 1 mM glutamate treatment resulted
in a phase advance of neuronal activity rhythms, with a mean shift of 2.66 +/- 0.21 h, n =
4 (Figure 3.2d). Concurrent application of 500 nM RAP with 1 mM glutamate blocked
these phase advances, with a mean phase shift of 0.67 +/- 0.3 h, n = 3 (t-test comparing
glutamate vs glutamate + RAP: n = 3, t5 = 5.601, p = 0.0025) (Figure 3.2e). RAP inhibited
glutamate-induced phase advances at ZT23 in a dose dependent manner, and 500 nM
RAP was necessary to block phase advances (Figure 3.2g) (one-way ANOVA: n = 3 to 4,
F(3,9) = 10.04, P = 0.0031). Selectively inhibiting LRP-1 with 75 μg/mL R2629 during 1 mM
glutamate treatment also prevented phase advances, with a mean phase shift of 0.67 +/0.33 h, n = 3 (t-test comparing glutamate vs glutamate + R2629: n = 3 to 4, t(5) = 5.304, p
= 0.0032) (Figure 3.2f). Neither RAP nor R2629 applied alone at ZT23 had any effect on
mean time-of-peak (Figure 3.2f). Collectively, these results demonstrate that LRP-1 is
required for glutamate-induced circadian clock phase shifting in mouse SCN in vitro.

3.4.3 RAP prevents glutamate-induced phase delays in tPA-/- mouse SCN tissue
Given LRP-1’s promiscuity, a variety of mechanisms could be responsible for its role in
circadian clock phase shifting.

LRP-1’s interactions with the plasminogen activating

system were a likely candidate for LRP-1 involvement in the SCN. We assessed whether
or not tPA is required for LRP-1’s role in phase shifting by repeating the RAP inhibition
experiments in SCN slices from tPA-/- mice. As above, SCN containing brain slices were
treated concurrently with 1 mM glutamate +/- 500 nM RAP and neuronal activity was
recorded the following day. As previously reported (Cooper et al., 2017), 1 mM glutamate
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applied at ZT16 induced a -3.13 +/- 0.65 h (n=4) phase shift in tPA-/- SCN brain slices
(Figure 3.3). Concurrent application of 500 nM RAP with 1 mM glutamate blocked these
phase delays, with a mean phase shift of a -0.58 +/- 0.35 h (n=6) (t-test comparing
glutamate vs glutamate + RAP: t(8) = 3.761, p = 0.0055), while 500 nM RAP applied alone
had no effect (mean phase shift = -0.167 +/- 0.167, n = 3). These results suggest that the
inhibition of glutamate-induced phase shifts by RAP does not involve preventing a tPALRP-1 interaction.

3.4.4 RAP treatment does not influence maturation of BDNF
To address the involvement of the tPA-BDNF-TrkB signaling cascade in another
way, we used western blotting to assess the effects of glutamate and RAP on BDNF
maturation in SCN tissue. Brain slices containing the SCN were treated with 1 mM
glutamate, 1 mM glutamate + 100 nM RAP, or 100 nM RAP. They were collected after a
5 min recovery period in normal EBSS and compared to no treatment controls collected
at the same time. There were no significant differences in total proBDNF (one-way
ANOVA: n = 6 to 10, F(3,27) = 1.524, p = 0.6566), total mBDNF (one-way ANOVA: n = 6 to
10, F(3,27) = 0.1511, p = 0.9132), or the mBDNF/proBDNF ratio (one-way ANOVA: n = 6 to
10, F(3,27) = 0.2497, p = 0.9838) across any of the treatments (Figure 3.4). Collectively,
these results suggest that not only does RAP not acutely change BDNF maturation
independently, but also that there are no acute changes in BDNF maturation following
glutamate treatment that require LRP-1.

3.4.5 RAP treatment does not change TrkB receptor phosphorylation on Y680
As a final way to assess the tPA-BDNF-TrkB signaling cascade, we used western
blotting to assess whether RAP treatment influences Trk receptor phosphorylation on
Y680/681, which also recognized the homologous residues Y706/707 on TrkB, as an
indicator of Trk receptor activation (Huang & Reichardt, 2003; Reichardt, 2006)(Wong et
al 2008. As before, SCN slices treated with 1 mM glutamate, 1 mM glutamate + 100 nM
RAP, or 100 nM RAP were compared to untreated control slices at ZT16. Once again, we
found no significant differences across any treatments (One-way ANOVA: n = 3, F(3,8) =
0.6715, p = 0.864) (Figure 3.5). These results suggest that inhibiting LRP-1 does not
influence TrkB receptor activation, and thus they reinforce the conclusion that the tPA60
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Figure 3-3. RAP blocks phase shift in tPA-/- SCN brain slices.

100 nM RAP prevents glutamate-induced phase delays in brain slices prepared
from tPA-/- mice. Shown are mean +/- SEM phase shifts induced by treatments
indicated applied to SCN slices prepared from tPA-/- mice. Phase delays plotted
as negative values. * p = 0.0055, n = 3 to 6.
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Figure 3-4. RAP treatment does not influence TrkB receptor phosphorylation.

TrkB receptor phosphorylation on Y680/681 does not change with 1 mM
glutamate, 1 mM glutamate + 100 nM RAP, or 100 nM RAP treatment at ZT16.
(A). Shown are representative blots of pTrkB (~140 kDa) and actin load control
(~41 kDa). (B). Mean +/- SEM pTrk(680/681) relative to actin, normalized to
control. No significant differences in one-way ANOVA, n = 3.
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Figure 3-5. RAP treatment does not influence BDNF maturation in SCN.

BDNF maturation does not change with 1 mM glutamate, 1 mM glutamate + 100
nM RAP, or 100 nM RAP treatment at ZT16. (A) Shown are representative blots
of proBDNF (~32 kDa), mBDNF (~14 kDa), and actin load control ( ~42 kDa) from
WT SCN which were treated as indicated. (B) Histogram showing proBDNF as a
ratio to actin, normalized to control. (C) Histogram showing mBDNF as a ratio to
proBDNF, normalized to control. (D) Histogram showing mBDNF as a ratio to
actin, normalized to control. No significant differences in one-way ANOVA: n = 6
to 9.
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BDNF-TrkB cascade is not the primary mechanism through which LRP-1 influences phase
regulation of the SCN circadian clock.

3.4.6 RAP treatment influences NR2B phosphorylation in SCN
Having eliminated the tPA-BDNF-TrkB cascade as the primary mechanism of LRP1 action in SCN clock phase shifting, we turned our focus to more direct interactions with
NMDAR. LRP-1 influences glutamate signaling partially by controlling NMDAR surface
localization (Maier et al., 2013), and therefore this could underlie LRP-1 functions in the
SCN.

We investigated whether RAP influences NR2B phosphorylation at Y1472 and

S1480, which are residues that influence NMDAR surface localization (Lim et al., 2002;
Prybylowski et al., 2005; Sanz-Clemente et al., 2013). Phosphorylation on Y1472 is
associated with increased localization of NMDARs to the cell membrane, and
phosphorylation on NMDAR S1480 is associated with increased internalization of
NMDARs. SCN slices treated with 100 nM RAP for 20 minutes at ZT16 were compared to
no-treatment controls via western blotting using phospho-specific antibodies for NR2B
Y1472 and S1480. 100 nM RAP treatment resulted in a decrease in NR2B S1480
phosphorylation (t-test control vs 100 nM RAP: n = 4, t(6) = 8.15, p = 0.002), and no
significant change in NR2B Y1472 phosphorylation (t-test control vs 100 nM RAP: n = 4,
t(5) = 0.3814, p = 0.7186) (Figure 3.6). Thus, these data suggest that inhibiting LRP-1
decreases NR2B phosphorylation on S1480.

3.4.7 Assessing effects of inhibiting LRP-1 on pCaMKII
To further explore whether LRP-1 modulates glutamate-induced phase shifts by
influencing NMDAR signaling, we investigated activation of CaMKII, an important early
step in the glutamate phase shifting cascade, by assessing glutamate-induced
phosphorylation of CaMKII T286 (Giese et al., 1998; Fukunaga et al., 2002). Initially we
compared untreated SCN brain slices with brain slices treated with 1 mM glutamate at
ZT16. Subsequently, we ran a more comprehensive set of experiments that included
treating SCN-containing brain slices at ZT 16 with 1 mM glutamate, 1 mM glutamate + 100
nM RAP, 100 nM RAP, or no treatment. In both cases we collected the tissue 5 minutes
after treatment, and conducted western blotting assays. Consistent with previous reports
(Yokota et al., 2001), our initial experiments confirmed that glutamate (1 mM) increases
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Figure 3-6. RAP treatment changes NMDAR phosphorylation patterns in mouse
SCN in vitro.
RAP treatment reduces phosphorylation of NR2B subunits at S1480, and does not change
phosphorylation on NR2B Y1472. (A) Shown are representative blots of pY1472 (~180
kDa) and load control actin (~42 kDa). (B) Histogram showing mean +/- SEM
pY1472/actin, normalized to first control on each blot. No significant differences in t-test,
n = 3 to 4. (C) Representative blots of pS1480 (~180 kDa) and load control actin. (D)
Mean +/- pS1480/actin, normalized to control on each blot. * p = 0.002, n = 4.
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pCaMKII T286 in the SCN (t-test: n = 3, t(4) = 4.716, p = 0.0092,) (Figure 3.7a-b). However,
in subsequent experiments comparing all 4 experimental conditions the relative
expression of pCaMKII was highly variable, so we found no significant differences across
treatments (One-way ANOVA: n = 5 to 6, F(3,19) = 0.3477, p = 0.8412, F3 = 0.2771) (Figure
3.7c-d).

3.5 Conclusion
Here, we present evidence that LRP-1 is expressed in the SCN, and that it is
necessary for glutamate-induced phase resetting of the circadian clock in the mouse SCN
in vitro. Additionally, we investigated several prominent LRP-1 interacting partners as
potential mediators of LRP-1 effects, with a specific focus on the plasminogen activating
cascade and intracellular signaling molecules downstream of NMDAR activation. We find
that LRP-1’s role in the SCN is independent of tPA, acute changes in BDNF maturation,
and TrkB receptor phosphorylation, effectively eliminating tPA proteolytic activity as a
central mediator of LRP-1 effects on phase shifting the circadian clock. We find that
inhibiting LRP-1 influences NMDAR phosphorylation patterns by reducing phosphorylation
on NR2B S1480, but we were unable to determine whether inhibiting LRP-1 influences
pCaMKII phosphorylation patterns.
LRP-1 is widely expressed throughout the central nervous system, but a direct
assessment of its expression patterns in the SCN had not previously been conducted
(Lillis et al., 2005). Western blotting shows LRP-1 expression in the SCN, as evidenced
by the presence of both the 515 kDa αLRP-1 and 85 kDa βLRP-1 subunits. Surprisingly,
we find differential expression patterns for the two subunits of LRP-1. Expression of the
extracellular αLRP-1 is higher at night than during the day, a pattern that persists to the
second day in vitro. Meanwhile, expression of the membrane-spanning βLRP-1 subunit
decreases in correlation with the time SCN brain slices are maintained in vitro. It is unclear
at this point how this is achieved and what physiological relevance it would have in vivo.
LRP-1 is transcribed as a full-length 600 kDa protein and then cleaved in the endoplasmic
reticulum into a 515 kDa αLRP-1 and 85 kDa βLRP-1, which remain non-covalently
associated on the cell surface (Lillis et al., 2005). The decrease in βLRP-1 over time in
vitro could be a response to tissue slicing injury. There is evidence that LRP-1 responds
to crush-injured rat sciatic nerves in the peripheral nervous system (Flutsch et al., 2016).
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Figure 3-7. Glutamate increases CaMKII phosphorylation at T286 in SCN.
(A). Representative images of pCaMKII and actin bands from control and glutamate
treated SCN slices, demonstrating glutamate-induced increase in CaMKII
phosphorylation. (B) Mean +/- SEM pCaMKII/actin normalized to control. *p = 0.0092, n
= 3. (C) & (D): Representative images of pCaMKII, total CaMKII, and actin bands from
SCN slices left untreated (C), or treated with 1 mM glutamate (G), 1 mM glutamate + 100
nM RAP (GR), or 100 nM RAP demonstrating variability in pCaMKII levels. (E). Mean +/SEM pCaMKII/actin normalized to no-treated control. No significant differences in Oneway ANOVA.
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Additionally, this response to injury could lead to increased internalization of the β subunit,
as LRP-1 could be serving a scavenging role in response to released proteins in the
extracellular space. This is reminiscent of the time-in vitro dependent increases in uPA
enzymatic activity observed previously in our lab (Cooper et al., 2017). These results
underscore the importance of controlling for multiple timing variables in circadian studies,
while further implicating the plasminogen activating cascade in a group of regulated
neuronal responses to injury (Mori et al., 2001; Flutsch et al., 2016; Diaz et al., 2017).
In contrast, the rhythm in αLRP-1 expression suggests there may be a circadian
influence on LRP-1 in the SCN. This is a first report of diurnal variations in LRP-1
expression, but interestingly Lrp-1 was identified as a circadian oscillating gene in liver
(Yan et al., 2008). αLRP-1 can exist in the extracellular space as “shed” LRP-1, which is
generated by proteolytic cleavage from the membrane-bound β subunit (Quinn et al.,
1997; Etique et al., 2013). The precise function of shed LRP-1 remains elusive, but it may
serve to sequester LRP-1 ligands in the extracellular space, thus controlling their activity
(Etique et al., 2013). It is somewhat perplexing that αLRP-1 expression increases during
the subjective night while βLRP-1 expression decreases. One possible explanation for
these results is that there are circadian changes in proteolytic cleavage of the extracellular
domain,

allowing

αLRP-1

to

accumulate

extracellularly

while

βLRP-1

is

internalized/degraded (Figure 3.8). LRP-1 shedding can be mediated directly or indirectly
by a variety of extracellular proteases, and at least on protease associated with increased
LRP-1 shedding, tPA, is known to have higher activity in the SCN at night than during the
day (Mou et al., 2009b; Etique et al., 2013; Cooper et al., 2017). Although LRP-1 has
been shown to recycle with near 100% efficiency (Van Leuven et al., 1980; Willingham et
al., 1980; Dickson et al., 1981), it is possible that following injury a different scenario exists.
A second possibility is that our data reflect changes in LRP-1 localization to lipid rafts
(Figure 3.8).

LRP-1 localization on the cell surface is dynamic, and it can localize

differentially to lipid rafts or clatharin coated pits depending on ligand or receptor
interactions (Wu & Gonias, 2005).

Association in lipid rafts could influence LRP-1

solubilization during protein extraction, which would mean our blots would reflect different
amounts of LRP-1 solubilized rather than a difference in expression. Although the source
of the differences in patterns of expression in the αLRP-1 vs βLRP1 are unclear, these
results suggest both diurnal regulation and injury regulation of LRP-1 expression in the
68

Figure 3-8. Potential models underlying differential α and β LRP-1 expression
patterns.
Option 1: 1) SCN slices are made in the morning, interrupting normal expression patterns
in the SCN with a slicing injury. 2) An increase in LRP-1 expression combined with an
increase in proteolytic activity as the SCN transitions into subjective night results in an
increase of shed αLRP-1 in the extracellular space. 3) A concurrent (or slightly delayed)
increase in LRP-1 internalization results in increased degradation of LRP-1, effectively
reducing the amount of βLRP-1 detected. This decrease persists into the second day in
vitro. Option 2: 1) In the subjective day, LRP-1 could localize outside of lipid rafts. 2) As
the SCN transitions to subjective night, and perhaps in response to slicing injury, there is
an increase in extracellular domain shedding combined with (3) a localization of LRP-1 to
lipid rafts. The result of this is more αLRP-1 detected on western blots, and a reduction
in the ability to solubilize βLRP-1 from the lipid rafts, resulting in reduced βLRP-1 in protein
extracts. The purpose of these two models is not to provide definitive answers for what is
happening in the SCN, but rather to provide possible explanations for the seemingly
impossible finding of differential patterns of immunolabeling in the LRP-1 subunits. To
fully understand LRP-1 expression in the SCN, it will be important to complete experiments
without the complication of slicing injury.
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SCN, and thus further investigation into LRP-1 expression patterns is warranted.
Importantly, there is a large amount of time between ZT6 (4 h in vitro) and ZT16 (6 h in
vitro) that is unaccounted for, and in which there could be changes that set the stage for
the differential expression patterns we observed here.
Along with assessing total LRP-1 expression, we also assessed LRP-1
phosphorylation on Y4507 using a phospho-specific antibody. Phosphorylation on this
residue is correlated with changes in LRP-1 endocytosis and signaling events, and thus
could be indicative of changes in LRP-1 activity rather than expression (Betts et al., 2008;
Guttman et al., 2009). We observe no circadian rhythm in LRP-1 Y4507 phosphorylation
and decreases that correlate with time in vivo, which is consistent with our observations
for βLRP-1, suggesting no differential phosphorylation in our system.
In an assessment of LRP-1 function in the SCN, we find that LRP-1 is required for
glutamate-induced phase shifting. We used two methods of inhibition to assess LRP-1:
non-selective inhibition with RAP and selective inhibition with antiLRP-1 antibody (R2629),
and both completely abrogate both early night glutamate-induced phase delays and late
night phase advances. While our data support LRP-1 involvement, RAP inhibits multiple
members of the LDLR family, and therefore it would be interesting to see if additional
LDLR family receptors are also involved in phase shifting. At both ZT16 and ZT23, the
inhibition by RAP is dose-dependent, although ~ 100nM RAP fully inhibits the phase
delays while >300nM RAP is needed to inhibit the phase advances. Phase delays and
phase advance involve different signaling mechanisms, and differential expression of
LRP-1 interacting proteins between early and late night could contribute to the differences
in dose responsiveness.
A plethora of evidence linking LRP-1 to the plasminogen activating system and Trk
receptors, and evidence supporting a critical role for the plasminogen activators in SCN
circadian clock phase shifting led us to hypothesize that LRP-1 modulation of circadian
clock phase shifting involves interactions with this pathway. We addressed this possibility
in three ways. First, we used tPA-/- mice to investigate whether tPA is necessary for RAP
to inhibit glutamate-induced phase shifting, and found that in tPA-/- mouse SCN brain slices
RAP is still able to block these phase shifts. This indicates that LRP-1 modulation of the
SCN circadian clock does not depend on interactions with tPA, although it doesn’t exclude
the possibility that tPA and LRP-1 interact in the SCN and have other effects relevant to
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the circadian clock. It appears that compensatory changes occur in tPA-/- mice in response
to the absence of tPA: despite tPA’s critical role in blood clotting, tPA-/- mice exhibit no
severe clotting phenotype (Carmeliet et al., 1994). In regards to the SCN circadian clock,
tPA-/- mice have minimal circadian phenotypic deficits, and uPA appears to serve a
compensatory role enabling glutamate-induced phase shifts (Cooper et al., 2017; Krizo et
al., 2018). It is possible that similar compensation masks our ability to detect a role for
the tPA/LRP-1 interaction in these animals. And finally, the tPA-/- mice used in this study
still express a portion of the tPA gene, thus non-proteolytic tPA effects cannot be excluded
(Carmeliet et al., 1994).
Second, to more directly assess the influence of LRP-1 on the tPA-dependent
proteolytic cascade, we assessed the effects of inhibiting LRP-1 on BDNF maturation. In
the SCN, BDNF acts to gate glutamate induced phase shifts downstream of tPA proteolytic
activity (Liang et al., 1998; Liang et al., 2000; Mou et al., 2009b). Thus, if LRP-1 acts
through modulating tPA proteolytic activity in the SCN, we would expect to see acute
changes in mBDNF generation following LRP-1 inhibition. Instead, we find no changes in
the relative amount of mBDNF, proBDNF, or the mBDNF/proBDNF ratio, indicating that
inhibiting LRP-1 does not influence BDNF maturation in the SCN in vitro.
Lastly, we investigated the effects of inhibiting LRP-1 on Trk receptor
phosphorylation as a marker of TrkB receptor activation. BDNF binding to TrkB receptor
causes it to dimerize and autophosphorylate several sites, including Y705Y706 (which is
homologous to Y680/680 on TrkA receptors), Y515, and Y816 (Poo, 2001; Huang &
Reichardt, 2003; Reichardt, 2006). This leads to signal transduction and activation of two
signaling cascades (MAPK/pCREB, and hosphatidylinositide 3-kinases (PI3K)/protein
kinase B (AKT)) (Cardenas-Aguayo Mdel et al., 2013). In the SCN, TrkB acts to gate
glutamate induced phase shifting following mBDNF binding (Allen et al., 2005). We find
that inhibiting LRP-1 using RAP does not change Trk receptor phosphorylation on
Y680/681. Thus, by assessing phase shifting in tPA-/- mice, BDNF maturation, and TrkB
receptor phosphorylation following RAP treatment we have convincingly demonstrated
that the tPA-BDNF-TrkB receptor cascade is not primarily responsible for RAP’s ability to
inhibit glutamate-induced phase shifting.

That said, these data do not rule out the

possibility that interactions between these proteins in the SCN mediate other clock
functions.
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A second prominent mechanism through which LRP-1 modulates glutamate
responses in other systems, particularly Schwann cells, is by controlling NMDAR surface
localization, as evidenced by aberrant NMDAR localization patterns in LRP-1 NPxY
mutant cell lines (Maier et al., 2013). Regulation of NMDAR localization is complex and
mediated by a variety of events, but a major contributor is phosphorylation on two NR2B
residues, Y1472 and S1480. Phosphorylation on NR2B Y1472 disrupts interactions with
clatharin coated pits (Prybylowski et al., 2005; Chen & Roche, 2007) and is associated
with

increased

membrane

localization

of

NR2B

containing

NMDARs,

while

phosphorylation on S1480 disrupts interactions with PSD95, thus increasing NMDAR
internalization (Chung et al., 2004). We assessed the influence of inhibiting LRP-1 on
phosphorylation of both residues in SCN brain slices. We find that RAP treatment does
not change phosphorylation on Y1472, but decreases phosphorylation on S1480. Given
the model above, these changes could suggest an increase of NMDAR on the cell surface
and thus enhanced rather than decreased NMDAR signaling. However, it is important to
note that NMDAR localization can be controlled independently of these phosphorylation
patterns. For example, NR2B phosphorylation patterns in Schwann cells are inconsistent
with observed changes in NMDAR localization, and suggested that the increases in NR2B
at the cell surface could be a direct effect of reduced LRP-1 internalization rate (Maier et
al., 2013). Regardless, these results suggest LRP-1 influences NMDAR localization
and/or other signaling properties in the SCN.

It will be important to assess changes in

NMDAR and LRP-1 surface localization in the future.
Finally, we assessed the influence of LRP-1 on CaMKII phosphorylation, which is
a key mediator of glutamate signaling downstream of NMDAR activation. Glutamate
induces CaMKII phosphorylation acutely in the SCN, and inhibiting CaMKII activation
prevents circadian clock phase shifts (Fukushima et al., 1997; Yokota et al., 2001;
Agostino et al., 2004). CaMKII interacts with the intracellular domain of LRP-1, and is a
key mediator of LRP-1 effects on axon guidance in the peripheral nerve growth cone and
thus it could be a key mediator of LRP-1 function in the SCN (Guttman et al., 2009;
Landowski et al., 2016). We found that treating SCN slices with 1 mM glutamate increased
CaMKII phosphorylation on T286, but in subsequent experiments to assess changes
following RAP inhibition we were unable to detect any significant changes, which may be
due to high variability in pCaMKII across samples. Across independent experiments, the
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patterns of phosphorylation were completely opposite of one another. The SCN is a
heterogeneous structure, and thus regional differences may be a source of this variability.
Assessing CaMKII activation using immunohistochemistry could provide more conclusive
answers.
The involvement of LRP-1 and potential rhythms in expression may provide some
clarity to some of our previous data. In investigating tPA and uPA expression and activity
in the SCN, we found different patterns for both proteases (Cooper et al., 2017). tPA
protein expression was rhythmic in the SCN, but we found no changes in tPA total
proteolytic activity. A rhythm in αLRP-1 could provide a mechanistic explanation for this.
It is possible that increased night-time αLRP-1 binds to tPA, which could serve either to
sequester tPA reducing its activity, or to act as a co-receptor increasing its activity.
Regardless of the function outcome, these findings were generated from the nonreducing/non-denaturing conditions of gel zymography, meaning that tPA complexed to
αLRP-1 may not dissociate on the gels. For uPA, we found its protein expression to be
constant, but its proteolytic activity increased during the time the tissue was maintained in
vitro. This correlates with the decrease we see in LRP-1 β subunit, suggesting that both
changes are a response to tissue injury, with related or independent of each other.
Teasing out these injury response mechanisms would be an interesting question, but is
beyond the scope of this research. Additionally, LRP-1 expression in the SCN may be
better assessed in a system without the consequence of injury.
Collectively, the data presented here demonstrate that LRP-1 is necessary for
glutamate-induced phase-shifting of the SCN circadian clock, and suggest that it may be
a mediator of daily iterative metaplasticity in the SCN. This study adds to accumulating
evidence that changes in the extracellular space are important for circadian clock
regulation. Through its endocytic and signaling activities, LRP-1 acts as a sensor and
regulator of the extracellular space.

It communicates changes in the extracellular

environment via signal transduction, and can regulate the concentrations of its ligands in
the extracellular space through endocytic functions.

More research is necessary to

determine the mechanisms underlying LRP-1 function in the SCN, but given its large and
diverse group of ligands and complex endocytic and intracellular responses, it is likely that
multiple interacting partners will be involved. Underscoring LRP-1’s complexity, we found
evidence excluding many of the canonical pathways central to both SCN function and
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LRP-1 mechanisms. The primary connections we found are, first, that RAP prevents a
glutamate response in the SCN that relies largely on NMDAR activity, and second RAP
induces a decrease in NR2B S1480 phosphorylation. It seems most likely that LRP-1 may
be attenuating the NMDAR signals, and it has been found that LRP-1 influences other
calcium channels, such as AMPARs and N-type calcium channels as well (Kadurin 2017,
Gan 2014). Addressing whether this is happening in the SCN will be an important next
step, and addressing the mechanisms through which LRP-1 can control calcium channels
is another salient question. An important next step will be to assess what ligands are
important for LRP-1 function in the SCN. Additionally, it will also be important to tease
apart the contributions of LRP-1 endocytosis vs signaling events in the mediation of
glutamate responses in the SCN. Use of neuronal specific LRP-1 knockout and LRP-1
NPxY mutant mice may assist in answering some of these questions.
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4 CONCLUSION: AT THE INTERSECTION OF LRP-1 AND
PLASMINOGEN ACTIVATORS - POTENTIAL MECHANISMS

75

4.1 uPA and LRP-1: Contributions to SCN circadian clock
phase regulation
Herein, we have expanded on the knowledge of proteins related to the
plasminogen activating cascade and how they participate in the process of phase shifting
the mammalian circadian clock in the SCN.

Although plasminogen activation was

originally studied for its role in the vascular system, many studies have identified its
members, including tPA, uPA, and LRP-1, as neuromodulators within the brain
(Fernandez-Monreal et al., 2004; Jeanneret & Yepes, 2017). Evidence demonstrating the
involvement of tPA in SCN circadian clock phase shifting has defined a role for this
pathway in modulating neuronal plasticity in the SCN and suggested that tPA-interacting
partners could also influence SCN neuronal activity (Mou et al., 2009a). The results
presented here are the first linking both uPA and LRP-1 to the SCN circadian clock.
Initially, we found that although inhibiting tPA with PAI-1 prevents glutamateinduced phase shifts in vitro, tPA-/- mice exhibit no severe circadian deficits. They exhibit
entrained behavioral activity rhythms in vivo and neuronal activity rhythms in vitro that
phase shift in response to light and glutamate pulses, respectively. The only phase
shifting deficit we observed is an increase in the time needed to entrain to a reversed light
dark cycle in the tPA-/- mice. The tPA-/- mice also exhibit a decrease in nocturnal wheelrunning activity, changes in activity patterns with food entrainment, and an increase it time
needed to entrain to a 6 hr advancement of LD cycle in vivo (Krizo et al., 2018). We
present evidence that uPA compensates for the loss of tPA in tPA-/- mice, enabling
glutamate-induced phase shifts in neuronal activity rhythms in vitro. Interestingly, this
functional compensation involves distinct cellular signaling mechanisms, as evidence
supports tPA but not uPA acting through a plasmin-BDNF dependent mechanism. Thus,
the processes underlying uPA’s compensatory processes remain unclear.
Second, we found that LRP-1 is necessary for glutamate-induced phase shifts of
the mouse SCN circadian clock in vitro.

Because tPA and LRP-1 act in concert to

influence neuronal plasticity in other regions, we hypothesized that these interactions
would be important for LRP-1’s role in phase shifting (Martin et al., 2008). However, we
find that tPA is not necessary for LRP-1’s permissive actions in glutamate-induced phase
shifting. Since NMDARs are a central mediator of glutamate-induced phase shifting in the
76

SCN, and LRP-1 can modulate NMDAR activity, we also focused our attention on the
intersection between LRP-1 and NMDAR (Ebling, 1996). We find that inhibiting LRP-1
influences NMDAR phosphorylation patterns, which implicates changes in NMDAR cellsurface localization.

Finally, we assessed CaMKII phosphorylation as a marker of

signaling events downstream of NMDAR activity in the SCN, but we were unable to
determine if inhibiting LRP-1 influences CaMKII activation.

Collectively, these data

implicate LRP-1 as an important regulator of clock phase shifting, but as with uPA, the
mechanism(s) remain elusive.
In this research we also evaluated uPA and tPA expression and proteolytic activity
in the SCN across the circadian day, and LRP-1 expression and phosphorylation patterns.
We find evidence of circadian rhythms in tPA expression but not proteolytic activity, no
rhythms in uPA expression or proteolytic activity, and potential diurnal variations in αLRP1 but not βLRP-1 subunits. Additionally, uPA activity and βLRP-1 expression exhibit
changes that correlate with the time slices are maintained in vitro, suggesting that a
response to tissue injury may occlude an accurate view of in vivo expression patterns in
the SCN. Importantly, these results demonstrate roles for both uPA and LRP-1 in the SCN
phase regulation, but both halves of the story leave open major questions regarding the
underlying mechanisms. In this chapter, I discuss potential overlap between these two
seemingly independent studies, and incorporate them into a model linking extracellular
events to the more extensively studied intracellular circadian clock mechanisms. And
finally, I highlight ways the plasminogen activators and LRP-1 may act together to
influence neuroplasticity in the SCN.

4.2 Bridging the gap – common signaling mechanisms of tPA,
uPA, and LRP-1
tPA, uPA, and LRP-1 all modulate neuronal activity, and can do so both
independently and through intersecting processes that aren’t fully understood and that are
likely both cell type and brain region specific. Points of overlap include regulation of the
extracellular matrix (ECM), influence on other extracellular proteases such as MMPs,
interactions with NMDARs, interactions with integrins, associations with uPAR, and
activation intracellular signaling pathways. Of particular importance to these studies are
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interactions between LRP-1 and uPA: uPA can bind to LRP-1 both alone and when bound
by PAI-1, and one intersection between LRP-1 and uPA are their interactions with uPAR.
4.2.1

Extracellular matrix plasticity in the brain
The ECM is an important modulator of neuronal activity and a source of overlap

for many tPA, uPA, and LRP-1 dependent functions. The ECM is a network of secreted
molecules interacting through protein-protein and protein-carbohydrate binding in the
extracellular space (Senkov et al., 2014; Jayakumar et al., 2017). ECM components
include chondroitin sulfate proteoglycans, heparin sulfate proteoglycans, collage, elastin,
laminin, fibronectin, and hyaluronic acid (Senkov et al., 2014; Jayakumar et al., 2017).
Additional secreted proteins, including growth factors, proteases, thrombospondins,
tenascin C and R, reelin, vitronectin, PAI-1, and chemokines can bind and modify the ECM
(Senkov et al., 2014; Jayakumar et al., 2017). Cell surface proteins and receptors,
including integrins, syndecans, agrin, lipoprotein receptors, and tetraspanins, also interact
with the ECM (Kerrisk et al., 2014). The ECM is considered a 4th component of a
tetrapartate synapse model, which consists of pre- and post-synaptic neuronal terminals
surrounded by a network of astrocytes and ECM molecules (Dityatev & Rusakov, 2011;
Smith et al., 2015). During development, the ECM acts to guide neuronal migration and
synapse formation, while in adulthood it is thought to stabilize and strengthen connections
(Pavlov et al., 2004). Moreover, remodeling of the ECM in adulthood can contribute to the
structural rearrangements necessary to change synaptic strength associated with long
term potentiation and long term depression (Senkov et al., 2014; Cooper, Submitted).
ECM remodeling is largely mediated by proteolytic cleavage, and can occur in both
physiological and pathological contexts (Lu et al., 2012).
Several lines of evidence support the concept that the ECM is an important part of
SCN plasticity. One intriguing finding is that there are daily rhythms in the ultrastructure
of the SCN; in particular astrocytic processes invade and retract from synapses on a 24
hr cycle (Becquet et al., 2008). This suggests that structural changes, which depend
heavily on ECM remodeling in other brain regions, are an important component of SCN
daily plasticity. Additional support for ECM involvement comes from the identification of
several ECM-interacting proteins in clock function. One class of ECM-interacting proteins
that has been investigated in the SCN are cell adhesion molecules (CAMs), which are
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membrane associated proteins that form adhesions with binding partners on adjacent
cells, or with the ECM itself (Thalhammer & Cingolani, 2014). Cell adhesion molecules
that have been implicated in SCN clock function include neural cell adhesion molecules
(NCAMs), neurexins, neuroligins, ephrins, Eph receptors, and cadherins (Cooper,
Submitted). As we will discuss below, the investigation of extracellular proteases including
tPA, uPA, and MMPs, as well as our data demonstrating a role for LRP-1, adds to the
evidence supporting a role for the ECM in the SCN.
4.2.2

Extracellular protease regulation of ECM: tPA, uPA, and MMPs
Many proteolytic enzymes cleave ECM macromolecules, including tPA, uPA,

(Andreasen et al., 2000) and MMPs (Murphy & Nagase, 2008). Through their proteolytic
activity, extracellular proteases influence the structure of the ECM, which in turn can
influence the strength of synaptic connections and modify neuronal responses. One way
tPA and uPA can influence ECM molecules is through plasmin-dependent functions (HoTin-Noe et al., 2009). Plasmin degrades many ECM macromolecules, including laminin,
fibronectin, and proteoglycans. Plasmin can also activate MMP’s, and indirectly affect
additional ECM molecules in this way (Mignatti & Rifkin, 1996; Legrand et al., 2001).
MMPs are a large family of zinc-dependent endopeptidases that can be secreted or
membrane-bound, and can degrade a variety of ECM molecules, including collagen,
gelatin, laminin, and fibronectin. tPA and uPA also influence the ECM by activating or
releasing growth factors such as latent-transforming growth factor β and vascular
endothelial growth factor from the ECM.
Our evidence demonstrating that plasminogen activation is important for SCN
clock phase regulation also implicates ECM remodeling as a component of circadian
timekeeping mechanisms. While the initial data supports a model whereby tPA acts via
BDNF signaling to enable phase shifts, uPA appears to be acting through BDNFindependent mechanisms (Mou et al., 2009a; Cooper et al., 2017). Additionally, uPA
compensation is not complete, as there are deficits in the ability of tPA-/- mice to re-entrain
to an inverted light cycle, and a reduction in ability to phase advance in vivo (Krizo et al.,
2018). Both of these findings raise the possibility that plasminogen activators act through
multiple pathways to influence the SCN circadian clock. This type of redundancy in SCN
in timekeeping mechanisms may have been evolutionarily selected for because problems
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with circadian rhythms are maladaptive. Additional evidence supporting ECM involvement
in the clock comes from research on MMPs in the SCN, which has found that inhibiting
MMP2/9 induces night-time phase shifts. The mechanisms through which the MMPs
modulate the SCN circadian clock appear to be complex, in that some of the inhibitorinduced phase shifts are independent of the plasminogen activating cascade, while others
require plasmin. Additionally, there may be diurnal variations in MMP9 proteolytic activity
in mouse and hamster SCN (Agostino et al., 2002; Abrahamsson, Submitted).
Collectively, tPA, uPA, and MMP2/9 involvement in circadian clock phase shifts support
the idea that extracellular proteases have diverse functions in the SCN, and ECM
modification may be a source of overlap. Rhythms in protease expression or activity could
correlate with rhythmic structural remodeling of ECM components, enabling the extension
and retraction of astrocytic processes, thus adjusting synaptic connections on a 24 hr
cycle.
4.2.3

Protease Inhibitors – unexplored partners
The activity of extracellular proteases can be regulated in two ways:

by

endogenous inhibitors and by receptor-mediated endocytosis to clear them from the
extracellular space (discussed below).

The plasminogen activators are inhibited by

serpins (serine proteinase inhibitors), including plasminogen activator inhibitors (PAI)-1
and -2, neurosperin, and protease nexin-1 (PN-1) (Huntington, 2011). PAI-1 is the main
inhibitor of plasminogen activators in the vascular space, but is weakly expressed in the
brain (Sawdey & Loskutoff, 1991; Masos & Miskin, 1997). PN-1 and neuroserpin are
expressed throughout the brain, and neuroserpin is considered the predominant PA
inhibitor in the nervous system (Osterwalder et al., 1996; Hastings et al., 1997; Krueger et
al., 1997; Kvajo et al., 2004; Samson et al., 2008). MMPs are inhibited by tissue inhibitors
of metalloproteinases (TIMPs) and adamalysins (a disintegrin and metalloproteinases,
ADAMs) (Wojtowicz-Praga et al., 1997). α2-macroglobulin is another protease inhibitor
that can act on many proteolytic enzymes, including tPA, uPA, plasmin, and MMPs
(Rehman et al., 2013). Many of these protease inhibitors have been found to influence
neuronal activity, which could involve protease inhibition or protease independent
interactions with receptors (Lee et al., 2008). Additionally, some of these (including
PAI1/2, TIMPs, α2-macroglobulin, and neuroserpin) bind to LRP-1, either independently
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or in complex with their target, and can be endocytosed or stimulate signaling pathways
(Lillis et al., 2008).
Although we have used these inhibitors to investigate tPA and uPA function in the
SCN, we have not yet investigated the endogenous roles these inhibitors may be playing.
Interestingly, PAI-1 mRNA and protein expression is rhythmic in the SCN in antiphase with
tPA rhythms, with high expression in the day and low expression at night (Menger et al.,
2005; Mou et al., 2009a). This suggests that PAI-1 may inhibit tPA activity during the day.
Additionally, vitronectin, which stabilizes PAI-1 in its active conformation, is necessary for
PAI-1’s inhibitory action on phase shifting, as PAI-1 doesn’t inhibit phase shifts in
vitronectin knockout mice (VN-/-) (Mou et al., 2009a). Interestingly, expression of PAI-1
also exhibits circadian rhythms in the periphery, and is thought to be regulated by the
TTFL, as CLOCK:BMAL heterodimers upregulate PAI-1 gene expression (Oishi et al.,
2007). These rhythms in PAI-1 contribute to hypo-fibrinolysis during the early morning
(Oishi et al., 2007). There is also preliminary data supporting neuroserpin expression and
function in the SCN (Conner and Prosser, unpublished). Much more work is needed to
elucidate the roles these protease inhibitors play in the SCN, and to what extent they
contribute to circadian clock phase regulation.
4.2.4

LRP-1 regulation of extracellular proteases
LRP-1 regulates extracellular signaling through several mechanisms, including

endocytic regulation of protease activity and interactions with ECM-associated proteins
(Etique et al., 2013). First, through its endocytic activity it internalizes proteases, including
uPA, tPA, MMP9 (Bu et al., 1992; Kounnas et al., 1993; Hahn-Dantona et al., 2001),
MMP2, and MMP13 (Barmina et al., 1999; Yang et al., 2001). LRP-1 can internalize these
proteins either before or after their inhibition by serpins or α2-macroglobulin (Strickland et
al., 2002).

This internalization can serve to regulate their proteolytic activity in the

extracellular space. For example, astrocytes can internalize tPA in an LRP-1 dependent
manner, and then recycle tPA back to the extracellular space through subsequent release
(Casse et al., 2012b). The internalization of tPA is inhibited by glutamate (Casse et al.,
2012b). Collectively, the cycle suggests that astrocytes control the amount of tPA in the
extracellular space through an LRP-1 dependent mechanism (Casse et al., 2012b).
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Although our data suggest that tPA is not required for LRP-1’s role in phase
shifting, it does not preclude the possibility that tPA and LRP-1 interact when tPA is
present, particularly given the many ways tPA and LRP-1 can interact. Given the diurnal
variations we see in αLRP-1, the increase in αLRP-1 at night could influence tPA activity
in a variety of ways (Figure 4.1).

First, it could allow LRP-1 to clear tPA from the

extracellular space, either before or after it is complexed with an inhibitor. LRP-1 recycling
of tPA could control amounts of tPA in the extracellular space in the SCN, thus controlling
its proteolytic activity. Alternatively, LRP-1 may enhance tPA’s proteolytic activity by
acting as a co-receptor. One study found that LRP-1 acts as a co-receptor to enhance
tPA cleavage of platelet derived growth factor-CC (PDGF-CC) in primary cultured cortical
microglia (Su et al., 2017). LRP-1 could use similar processes to regulate uPA or MMP
activity in the SCN, as it binds and endocytoses them as well. Regardless of the specifics,
LRP-1 dependent regulation of extracellular proteolytic activity could align nicely with our
studies on LRP-1 and the plasminogen activators in the SCN.
4.2.5

LRP-1 influences expression and function of ECM-interacting proteins
A second way LRP-1 influences ECM composition is by regulating ECM-interacting

proteins. Cell-associated proteins that can be regulated by LRP-1 include integrins and
uPAR, which may have both independent and overlapping roles. Interactions with these
two molecules are points of overlap between LRP-1 and uPA that will also be highlighted
here.
uPAR
uPAR is a GPI-anchored membrane receptor that is important for many uPA
functions. uPA binding to uPAR allows plasmin to cleave uPA into its active form, thus
increasing uPA proteolytic activity (Lijnen et al., 1987a; Lijnen et al., 1987b). Additionally,
uPAR can mediate signaling events through co-receptors (Lino et al., 2014). LRP-1 and
β1-integrin are two co-receptors that enable uPAR signaling events in neuronal systems,
particularly in promoting axonal recovery following a CNS injury (Merino et al., 2017a).
LRP-1’s interactions with uPAR are complex. In some contexts, LRP-1 modulates uPAR
surface localization by endocytosing uPA-serpin complexes that are simultaneously
bound to uPAR and LRP-1 (Conese et al., 1995). This can serve to control uPA and uPAR
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Figure 4-1. Model depicting extracellular protease interactions.
During the day, when lower levels of αLRP-1 are detected, LRP-1 may serve to
endocytose extracellular tPA. At night, when levels of αLRP-1 are high, it may also
endocytose tPA, but there could be increased recycling back to cell surface. tPA levels
are higher at night, and this could stimulate LRP-1 endocytic activity, shedding, or
signaling events. Additionally, LRP-1 may act as a co-receptor increasing tPA proteolytic
activity at night.
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activity, as discussed above. LRP-1 can also mediate cell signaling through uPAR. In
other contexts uPA binding to uPAR doesn’t result in LRP-1 mediated endocytosis of the
complex, but rather initiates LRP-1 dependent recruitment of β1-integrin to the neuronal
membrane (Merino et al., 2017a). The uPA-uPAR-LRP-1-integrin complex then mediates
Rac1 activation, which can influence axonal regeneration (Merino et al., 2017b).
Separately, binding of uPA to uPAR increases their affinity of uPAR for vitronectin and
integrins, which promotes cell adhesion (Kanse et al., 1996; Etique et al., 2013).
Interactions via uPAR could serve as a link between uPA and LRP-1 in the SCN.
First, involvement of uPAR may underlie uPAs compensatory action on circadian clock
phase shifting, which remains elusive. We have preliminary data suggesting uPAR is
expressed in the SCN, and that its expression levels do not exhibit circadian rhythms.
However, a functional assessment of uPAR in the SCN has yet to be completed. Future
experiments could address uPAR involvement in circadian clock phase shifting,
investigate interactions between uPAR and LRP-1 proteins, and determine if inhibiting
LRP-1 influences uPAR expression in the SCN.
Integrins
LRP-1 and uPA function are also linked through interactions with integrins. Not
only do they work in concert with uPAR to influence integrin trafficking, as discussed
above, but they also each influence integrin function in other ways. Integrins are
heterodimeric transmembrane receptors that mediate cell-cell and cell-ECM adhesions.
Integrins are expressed in mature synapses, where they coordinate synapse structure and
function in response to changes in the extracellular environment. Integrins regulate
synaptic transmission by affecting synaptic strength and neuronal excitability (Park &
Goda, 2016).

For example, they can control the number and composition of AMPA

receptors (Pozo et al., 2012), and can enhance NMDAR activity by regulating
phosphorylation of GluN2A and GluN2B NMDAR subunits (Chavis & Westbrook, 2001;
Shi & Ethell, 2006). Changes in integrin binding also leads to changes in dendritic spine
shape (Park & Goda, 2016). Additionally, they are necessary for MMP9 to increase lateral
diffusion of GluN1 subunits between synaptic and extrasynaptic sites, which influences
NMDAR responses to glutamate (Michaluk et al., 2009). Collectively, integrins seem to be
a crucial member of the extracellular milieu that influences neuronal plasticity.
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uPAR interacts with various integrin subunits, including β1, β3, and β6, and these
interactions can mediate some of uPARs neuronal functions (Eden et al., 2011). β1
integrin is a receptor for fibronectin, which is required for uPA/uPAR functions such as
promoting axonal regeneration (Diaz et al., 2017). uPA induces recruitment of β1 integrin
to the plasma membrane in cerebral cortical neurons, and β1 integrin neutralizing
antibodies block effects of uPA-uPAR binding on axonal repair (Merino et al., 2017a). So,
interactions between β1 integrin and fibronectin mediate uPA-induced neurorepair.
LRP-1 also associates with integrins, and this interaction can modify integrin
activation, trafficking, degradation, and downstream signaling (Wujak et al., 2017). LRP1 mediates integrin activity by mediating their internalization or influencing their maturation
and localization to the cell surface (Lillis et al., 2008; Wujak et al., 2017). In some cases,
this involves interactions with uPAR (Czekay & Loskutoff, 2009). In other cases, it is a
direct association, such as when LRP-1 associates with β2-integrins on leukocytes; this
interaction is thought to regulate integrin recycling during macrophage migration (Cao et
al., 2006). LRP-1 can also play a role in delivery of integrins to the cell surface (Theret et
al., 2017). Loss of LRP-1 correlates with reduced cell-surface expression of β1-integrin,
but not total β1 integrin (Salicioni et al., 2004; Spijkers et al., 2005; Cao et al., 2006).
Interestingly, RAP does not affect integrin maturation, suggesting that LRP-1’s regulation
of integrin maturation does not require ligand binding or endocytosis (Salicioni et al.,
2004). LRP-1 could associate with chaperones or adaptor proteins to mediate this effect,
because LRP-1 is not co-immunoprecipitated with β1 integrin. Chaperones or adaptor
proteins such as hsp90, Fe65, or ICAP-1 might act as a bridge between LRP-1 and integrin
(Salicioni et al., 2004), and LRP-1’s effects sometimes depend on other molecules such
as thrombospondin, tPA. Integrins have not yet been assessed in the SCN. However,
given their ability to modulate neuroplasticity, the involvement of other cell adhesion
molecules (CAMs) in the SCN, and their close associations with proteins in this research,
an investigation of integrins in the SCN seems warranted.

4.3 To shift or not to shift – decision making in the SCN
One key question remaining regarding SCN timekeeping is how it generates such
dramatically different responses to stimuli over the course of the day. The same stimulus
(light or glutamate) induces phase advances and delays when applied at night, but not
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during the day, indicating that there are 24 hr cycles in neuronal responsiveness in the
SCN. The current models explaining this plasticity focus on several proteins, including
BDNF, TrkB, NMDARs, and various intracellular effectors. However, many modulators of
neuroplasticity identified in other regions remain uninvestigated in the SCN. The ECMassociated processes and astroglial rhythms discussed above likely contribute to the daily
plasticity in the SCN. Additionally, our finding that inhibiting LRP-1 prevents glutamateinduced phase delays suggests that the ECM may contribute to this decision making
process in the clock. Because of LRP-1’s complexity, it implicates many molecules as
potential regulators of this function. Above, I discussed ECM associations as a potential
mechanisms underlying LRP-1s role in phase shifting, and here I will focus on receptor
interactions that could enable these phase shifting decisions. In particular, LRP-1 may act
by modulating NMDAR calcium signaling in the SCN.
4.3.1

LRP-1 and NMDAR
NMDARs modulate neuroplasticity throughout the CNS, and in the SCN clock

phase shifting relies heavily on NMDAR signaling.

NMDAR-based calcium-influx is

required for glutamate-induced phase shifting, as inhibiting NMDARs prevents these
phase shifts and NMDA administration induces night-time phase shifts (Colwell, 2001).
While there are data supporting rhythms in NMDAR expression patterns and
phosphorylation in the SCN (Bendova et al., 2012), many questions remain unanswered
regarding how NMDARs are regulated in the SCN, and thus how they contribute to daily
iterative changes in neuronal responsiveness.
We have found that inhibiting LRP-1 prevents glutamate induced phase shifts,
which means that we are preventing a process that depends on NMDAR signaling.
Inhibiting LRP-1 attenuates NMDAR calcium influx in other systems (Mantuano et al.,
2013). Thus, the mechanism through which LRP-1 is acting may involve changes in
NMDAR responses, which could be achieved through several mechanisms. A first set of
possibilities relates to a direct influence of LRP-1 on NMDAR localization (Figure 4.2).
LRP-1 can physically connect to NMDAR via PSD95 (May et al., 2004). LRP-1 can
regulate the surface distribution and internalization of NR2B-containing NMDAR
receptors, which may be the source of its permissive role in phase shifting (Maier et al.,
2013). One possible model is that LRP-1 increases the amount of NR2B-containing
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Figure 4-2. LRP-1 NMDAR interactions
Models demonstrating ways that LRP-1 could influence NMDAR signaling. Synaptic
localization: During the day, LRP-1 may mediate internalization of NMDARs or lateral
diffusion away from the synapse, thus preventing phase shifts to glutamate. LRP-1 may
recruit NMDARs to the synapse during the night, enabling shifts. Co-receptor recruitment:
During the day, LRP-1, NMDAR, and TrkB function independently. At night, increased
tPA stimulates LRP-1 recruitment of NMDAR via interactions with PSD-95, and
transactivates TrkB receptors, enabling phase shifting responses to glutamate.
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NMDARs on the cell surface during the night, placing them in a prime location to be
activated by glutamate and thus allow phase shifts to occur. During the daytime LRP-1
may mediate the internalization of NMDARs, thus attenuating glutamate-induced
responses.

Our finding that inhibiting LRP-1 with RAP changes NR2B subunit

phosphorylation patterns supports the idea that LRP-1 influences NMDAR surface
localization. However, our data are slightly counter-intuitive.

We find a decrease in

phosphorylation on S1480 when we inhibited LRP-1 with RAP, which has been found to
correlate with increased rather than decreased NMDAR cell surface localization. The
original study assessing LRP-1 influence on NMDAR localization also found patterns of
NMDAR phosphorylation that did not align with their receptor localization data
demonstrating a reduction in NMDARs on the cell surface (Maier et al., 2013). Regulation
of NMDAR localization is complex, and it is possible that LRP-1 circumvents classical
surface localization mechanisms by physically pulling NMDARs into the cell during their
endocytic activities. A second possibility relates to the finding that LRP-1 can localize both
in lipid rafts and in clathrin coated pits, and can move laterally in and out of the synaptic
regions (Laudati et al., 2016). Thus, instead of internalizing NMDARs, LRP-1 could also
change their synaptic vs. extrasynaptic localization, and these changes may regulate
glutamate phase shifting responses across the day. Synaptic vs extrasynaptic localization
is an additional mechanism that influences glutamate signaling responses (SanzClemente et al., 2013). Directly assessing cell surface dynamics of NMDARs and LRP-1
over the course of the day and/or in response to RAP treatment could provide some insight
into these scenarios in the SCN.
Finally, although it has not been investigated with respect to LRP-1 activity,
another key regulator of NMDAR signaling properties is NMDAR subunit composition.
NMDAR subunit composition varies throughout the CNS and changes depending on
neuronal activity. NMDARs consist of GluN1 subunits paired with one of four GluN2
subunits (GluN2A-D). The four GluN2 subunits are largely responsible for functional
heterogeneity. GluN2A and GluN2B are thought to have central roles in synaptic plasticity
(Paoletti et al., 2013). NMDAR subunit composition also varies according to cellular
localization. Generally, synaptic NMDARs contain GluN1/GluN2A, and heterotrimeric
GluN1/GluN2A/GluN2B receptors, while extrasynaptic NMDARs contain a higher
proportion of GluN2B subunits, although this is a drastic oversimplification. NMDARs are
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mobile, and lateral diffusion can contribute to changes in NMDAR activities (Paoletti et al.,
2013). NMDAR subunit composition is highly plastic, and changes in subunit composition
is an additional mechanism fine-tuning NMDAR responses (Paoletti et al., 2013).
Individual NMDAR subunits exhibit rhythmic patterns of expression in the SCN.

In

particular, total NMDAR and NR2A subunit expression is higher at night, and in general
NMDAR activity is higher at night than in the day in the SCN (Bendova et al., 2009).
Given the ability of LRP-1 to affect so many other NMDAR functions, it is possible that it
contributes to the recruitment of specific NMDAR subunits – a concept that has yet to be
explored.
4.3.2

LRP-1 – NMDAR – Trk receptor complexes and their relevance to clock phase
shifts
In addition to influencing NMDAR localization, LRP-1 acts in conjunction with

NMDARs and Trk receptors as co-receptors to induce signaling events in response to
extracellular ligands (Mantuano et al., 2013). For example, NMDAR can function as an
LRP-1 coreceptor to promote Schwann cell survival and migration (Mantuano et al., 2015).
LRP-1, NMDAR, and Trk receptors assemble to form a unique co-receptor system that
integrates signaling events in response to LRP-1 ligands (Mantuano et al., 2013). LRP-1
cell signaling is ligand dependent, and this may be in part because different ligands induce
different receptor co-recruitment (Mantuano et al., 2013).
Another important LRP-1:Trk ligand is a2-macroglobulin. The ability of a2macroglobulin to promote neurite outgrowth on PC12 cells, N2a cells, and cerebellar
granule neurons requires both LRP-1 binding and Trk receptor transactivation via SFKs
(Shi et al., 2009). a2-macroglobulin binding to LRP-1 induces Trk phosphorylation in an
SFK dependent manner.

SFK antagonism or Trk receptor inhibition prevents the

responses mediated by a2-macroglobulin and tPA, which includes ERK1/2 activation and
neurite outgrowth. So, a2-macroglobulin stimulated LRP-1-dependend Trk transactivation
may be a distinct pathway influencing cell signaling without NMDARs (Rebeck, 2009). In
PC12 and N2a neuron-like cell culture tPA induces ERK1/2 activation in two phases, one
that is LRP-1 dependent and rapid, and a slower one that is independent of LRP-1
(Mantuano et al., 2013). The LRP-1 dependent phase involves both NMDAR and Trk
receptors, which function as a single signaling system (Mantuano et al., 2013). Inhibiting
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either NMDAR with MK801 prevents tERK1/2 activation, and it prevents tPA or a2macroglobulin induced phosphorylation of Trk receptors (Mantuano et al., 2013). So the
data support a model where some LRP-1 ligands (but not all), recruit NMDARs as a
coreceptor to stimulate transactivation of Trk receptors, with the conclusion being that all
three work in conjunction to mediate ERK1/2 activation (Mantuano et al., 2013). It is also
interesting to note that PSD-95 is recruited to LRP-1 following tPA or α2-macroglobulin
treatment. While this was demonstrated with TrkA receptors in neuron-like cells, it is
plausible that a similar receptor platform involving TrkB receptors mediates signaling in
the SCN. Each of these proteins is implicated independently in gating phase shifting: tPA
levels increase at night and this is necessary for glutamate-induced phase shifts in vitro,
NMDARs are the primary receptor mediating photic/glutamate phase shifts, TrkB
receptors are necessary for glutamate phase shifts, and here we have demonstrated that
LRP-1 is also required for phase shifting. A possible model is that high night-time tPA
expression allows it to bind to LRP-1, mediating signaling events that require both NMDAR
and TrkB receptors, that ultimately lead to downstream signaling events (Figure 4.2). The
recruitment of this complex could also serve to increase neuronal responses to glutamate.
As with the other possibilities described, this model could overlap with additional models
(Figure 4.3).
4.3.3

LRP-1 and AMPA
Finally, it is worth mentioning that LRP-1 can also interact with AMPA receptors.

AMPARs are also important for LTP and LTD and are regulated largely through
phosphorylation and de-phosphorylation of their c-terminal domain (Lee et al., 2000).
AMPA receptors traffic rapidly, moving through endocytic pathways, sorting to degradation
pathways or being recycled back to the plasma membrane (Huganir & Nicoll, 2013), where
they influence dendrite and spine motility and contribute to synaptic plasticity. AMPA
receptors participate in photic phase shifts by acting upstream of NMDAR, probably by
removing a magnesium block (Mintz et al., 1999; Mizoro et al., 2010).

Conditional

neuronal knockout of the Lrp1 gene decreases level of GluA1 mRNA and protein in the
brain (Liu et al., 2010).

LRP-1 can also influence the cellular distribution, turnover and

phosphorylation of GluA1, and this influences calcium influx, neurite outgrowth, and
filipodia formation in neurons (Gan et al., 2014). GluA1, LRP-1 and PSD95 form
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Figure 4-3. Model of LRP-1 and plasminogen activator interactions in the SCN.
LRP-1, tPA, and uPA interact in a variety of ways to mediate glutamate-induced phase
shifting in the mammalian SCN. Known interactions include tPA or uPA plasmindependent generation of mBDNF, activating TrkB receptors, and enabling NMDARdependent glutamate-induced phase shifts. LRP-1 is also required for phase shifting in
vitro, but the mechanism is unclear. Potential interactions relevant to SCN clock function
include associations with NMDARs via PSD95 and transactivation of Trk receptors.
Ligand binding to LRP-1 may result in a variety of consequences, including ligand
endocytosis, recycling, degradation, and/or activation of intracellular signaling. Shed LRP1 in the extracellular space may also impact LRP-1 ligand function. Interactions with uPAR
or integrins could also regulate phase shifts, and their role could involve interactions with
the ECM. Much more work is necessary to fully understand how these proteins act in
concert to coordinate phase shifting responses in the SCN.
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complexes, similar to those seen with NMDARs, and these could influence AMPA receptor
recycling (Gan et al., 2014). Whether or not LRP-1 is influencing AMPARs in the SCN is
another question that remains to be explored.
4.3.4

Global considerations for LRP-1
Although our study of LRP-1 focuses on SCN timekeeping mechanisms, a more

global role for LRP-1 in daily rhythmicity throughout the body should not be ignored. LRP1 responses are largely context dependent, and circadian rhythms in cellular signaling
seem to be the norm, not an exception. With that in mind, understanding how LRP-1
functions across the day may be important to understand its physiological influence.
Additionally, our data indicate LRP-1 does not simply respond passively to extracellular
changes, but serves to regulate time-keeping decisions. If we are to extrapolate this
finding to the remainder of the body, it will be important to understand how circadian timing
influences LRP-1 effects, and LRP-1 influences the timing of physiology. With that in
mind, there are several tantalizing connections for which LRP-1 and an understanding of
LRP-1 in clocks could have translational benefits.
4.3.5

Metabolic syndrome
First, disruptions in both LRP-1 and circadian rhythms are associated with

development of metabolic syndrome, which is a series of physiological, metabolic, and
biochemical risk factors for type 2 diabetes and cardiovascular disease (Au et al., 2017).
LRP-1 is involved in insulin signaling and glucose homeostasis, both of which are
massively disrupted in metabolic syndrome and associated pathologies (Au et al., 2017).
Shift work disorder (a case of chronic circadian disruption) is also associated with an
increased prevalence of metabolic syndrome (Tarquini & Mazzoccoli, 2017). Glucose
homeostasis also contributes to SCN clock function, and in turn the clock regulates daily
timing of glucose metabolism (Ruiter et al., 2006; Dibner & Schibler, 2015). Much more
work needs to be done to fully connect the pieces of this enormous puzzle, but our data
demonstrating a role for LRP-1 in circadian rhythms suggest that it could be a prime
candidate linking the processes.
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4.3.6

Alzheimer’s disease
LRP-1 and circadian rhythms also overlap in the context of Alzheimer’s disease

development and progression.

LRP-1 regulates the metabolism of amyloid-β, and

preclinical studies suggest that LRP-1 plays a role in regulating apolipoprotein-E (APO-E)
pathogenesis, though the precise roles of LRP-1 remain elusive in this context as well
(Shinohara et al., 2017). Circadian disruptions, notably changes in the sleep-wake cycle,
are also associated with neurodegenerative disorders such as Alzheimer’s disease;
though the jury is still out regarding which component is the causative agent (Musiek &
Holtzman, 2016). Given that LRP-1 is being proposed as a therapeutic target for AD, and
that the roles of LRP-1 are context dependent (Shinohara et al., 2017), the circadian
contributions to LRP-1 function, both in the brain and throughout the periphery may be
important to untangle for optimal therapeutic benefit. With the intriguing proposal that
Alzheimer’s disease can be characterized as type 3 diabetes because of insulin
dysregulation in the brain, the associations between LRP-1, circadian rhythms metabolic
disorders and dementia increase (de la Monte & Wands, 2008).

4.4 Final conclusions
In conclusion, here we have presented two independent studies, one finding that
uPA can compensate to allow phase shifting in tPA-/- mice, and the other showing that
LRP-1 is necessary for glutamate induced phase shifts of SCN neuronal activity rhythms
in vitro. While the plasminogen activators and LRP-1 overlap in some functions, they also
have distinct effects on neuronal systems, and it will be important to untangle the
mechanisms underlying the roles of each in the SCN. While uPA expression is low in the
brain, the finding that uPA is required for a normal neuronal response in tPA-/- mice
suggests that a closer look at uPA’s physiological role, in addition to its pathological roles,
may be warranted.
On a different note, our finding that LRP-1 is involved in circadian clock phase
shifting the first indication of a protein with its capabilities involved in timekeeping
mechanisms. LRP-1 (and other LDL receptors) are unique in their endocytic and signaling
capabilities. LRP-1 binds a large and diverse range of ligands, and mediates a complex
array of events following ligand binding, including endocytosis, signal transduction, and
co-receptor recruitment. LRP-1 functions are context dependent, and in the SCN context
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changes dramatically over the course of 24 hours. LRP-1 could be simply responding to
the changing extracellular environment of the SCN, nonselectively binding ligands based
on what is most available in the ECM. However, such a passive role doesn’t explain why
blocking ligand binding prevents phase shifts. This result suggests that somehow LRP-1
is communicating information to make a decision on whether or not to shift. Understanding
what ligands and what intracellular effectors are involved will be important to fully
understand LRP-1’s role in the clock, where LRP-1 may serve as both a surveyor and
regulator of extracellular space in the SCN.
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